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At 1 year:       
Remained in active surveillance program  101 (74.8)  107 (89.2)   
Dropped out due to disease progression  0  0   
Dropped out with no disease progression  34 (25.2)  13 (11.2)   0.003 
       
At 5 years:       
Remained in active surveillance program   62 (45.9)  68 (56.7)   
Dropped out due to disease progression  17 (12.6)  26 (21.7)    






























  OR (95% CI)  OR (95% CI)  OR (95% CI) 
Educational seminar       
no  1.00  1.00  1.00 
yes  0.21 (0.09‐0.49)  0.25 (0.12‐0.51)  0.26 (0.12‐0.56) 
       
Age (continuous)  1.03 (0.98‐1.09)  0.94 (0.91‐0.98)  0.93 (0.90‐0.98) 
       
PSA (continuous)  0.94 (0.88‐ 1.01)  0.96 (0.52‐1.01)  0.98 (0.93‐1.04) 




GGG1  1.00  1.00  1.00 
GGG2  0.44 (0.20‐0.97)  0.49 (0.23‐1.00)  0.48 (0.22‐1.02) 
       
DRE        
Benign  1.0  1.00  1.00 
T2  0.88 (0.43‐1.79)  0.98 (0.54‐1.77)  0.93 (0.50‐1.72) 










































































































































































































































































































































































3+3  Not recorded  (33% of total cores)  No  (50%)  TRUS 
PRIAS  
(125) 



































































































































3+3  10  <20% of total cores  No  6mm (<30%)  No 
Goteborg  
(131) 
T1c (VLRPC)  Any  0.15  3+3  10 (6 up to 2009)  <3  No   (<50%)  No 
  T1(LRPC)  <10   ‐  3+3   10 (6 up to 2009)   Not recorded  No   Not recorded  No  







‐  <0.15  3+3  10 (within a year) 
or x2 biopsies ‐ one 
within a year) 


















2  No  <50%  No 
  T2b‐T2c 
(HRPC) 





























































































































































6/12  6/12  ‐  ‐  ‐  ‐  12  12/12  Annually 























































































































































































Study  Gleason Score  Positive cores No. (%)  Maximum cancer 
length (MCL) 
PSAV  PSADT (yr)  DRE 
MSKCC (122)  >6  >3  >50%      ‐ 
John Hopkins (123)  >6  (>33% of total cores)  >50%  ‐  ‐  ‐ 
UCSF (124)  >6  >2  ‐  ‐  <3  ‐ 




MCL  ‐  ‐  ‐ 
Royal Marsden (127)  4+3  (>50% of total cores)  ‐  >1ng/ml per year  ‐  ‐ 
ProtecT (107)  50% in PSA increase triggered review   
University of Toronto 




(129)  4+3  >3  ‐  ‐  <3  ‐ 
St Vincents, Australia  (130)  >6  (>20%)  >8mm  >0.75  <3  T2b 
Goteborg (131)  Any gleason or TNM 






>3+4 (IRPC, HRPC)  >2  (34%)  ‐  ‐  ‐ 
Milan (SA‐INT + PRIAS) (133)  >6 (SAINT) 
>20of cores (up to 2012), 
>25% cores (2012‐2016)  >50%  ‐  <3  >T2c 
  >6 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































19  Loeb, et al  2016  (35) 
 












































































































































































































































































































































































































































































































4  Yes  Yes  Yes  No  Yes  
CO 
Goh et al, 2012,  
USA  3  Yes  Yes  Yes  No  No 
CO/Q 
Orom et al, 2014,  
USA  4  Yes  Yes  Yes  No  Yes 
CO 
Xu et al, 2016,  





USA  4  Yes  Yes  Yes  No  Yes 
CO 
Anandadas et al, 2011,  
UK   3  Yes  Yes  No  No  Yes 
SG 
Gorin et al, 2011,  
USA  3  Yes  No  Yes  Yes  No 
CO 
Loeb et al, 2016,  
USA  3  Yes  No  Yes  Yes  No 
Q 
Volk et al, 2014,  
USA  3  Yes  Yes  Yes  No  No 
Q 
Xu et al, 2012,  
USA  3  Yes  No  Yes  Yes  No 
Q 
O’Callaghan et al, 2014, 
Australia  3  Yes  No  Yes  Yes  No 
Q 
Mishra et al, 2013,  
USA  3  No  No  Yes  Yes  Yes 
SPO 
Ehdaie et al, 2017,  
USA  4  No  Yes  Yes  Yes  Yes 
SPO 
Venderbos et al, 2015, 
Netherlands  4  Yes  No  Yes  Yes  Yes 
SG 
Venderbos et al, 2017, 




4  Yes  No  Yes  Yes  Yes  CO 
Kendel et al, 2016, Germany   4  Yes  Yes  Yes  No  Yes  CO 
Vasarainen et al, 2012, 
Helsinki  
4  Yes  No  Yes  Yes  Yes  SG 
Bellardita et al, 2013,4 
Italy 4 
4  Yes  No  Yes  Yes  Yes  SG 
Vanagas, 2013, 
Lithuania  
3  Yes  No  Yes  No  No  SG 
Hegarty et al, 2008,  
USA and Ireland  
3  Yes  No  Yes  Yes  No  SG 
Smith et al, 2009,  
Australia 
3  Yes  No  Yes  Yes  No  SG 
Parker et al, 2016,  
USA  
4  Yes  Yes  Yes  No  Yes  SG 
Punnen, 2013, USA,   4  Yes  Yes  Yes  No  Yes  SG 
Lane et al, 2016,  
UK  
4  Yes  Yes  Yes  No  Yes  CO 
Van den Bergh et al, 2010,  
Netherlands  
4  Yes  No  Yes  Yes  Yes  SG 
















Xu et al, 2016,USA  4  Yes  Yes  Yes  No  Yes  CO 
Wilcox et al, 2014, 
Australia 
4  Yes  No  Yes  Yes  Yes  SG 
Burnet et al, 2007,  
UK 
4  Yes  No  Yes  Yes  Yes  SG 
Davison et al, 2011, 
Canada 
3  Yes  No  Yes  No  No  CO 
Anderson et al, 2014, 
Australia 
3  Yes  Yes  No  No  Yes  SG 
Oliffe et al, 2009,  
Canada  
3  Yes  Yes  No  yes  No  CO 
Berger et al, 2015,  
USA 
3  Yes  Yes  No  No  Yes  Q 
Seiler et al, 2012, 
USA  
4  Yes  No  Yes  Yes  Yes  CO 
Kinsella et al, 2015,  
UK  
3  No  Yes  No  Yes  Yes  SPO 
Wade et al, 2015,  
UK  
3  Yes  No  Yes  Yes  No  CO/Q 
Kazer et al, 2011 
USA 
4  Yes  No  Yes  Yes  Yes  Q 
Wade et al, 2013,  
UK 
3  Yes  No  Yes  Yes  No  SG 
Wade et al, 2015, 
UK 
3  Yes  No  Yes  Yes  No  Q 
Latini et al, 2007, 
USA 
4  Yes  Yes  No  Yes  Yes  CO 
Jeldres et al, 2015,  
USA  
3  Yes  No  Yes  No  Yes  SG 
Donovan et al, 2016, UK  4  Yes  No  Yes  Yes  Yes  SG 
Loeb et al, 2017, USA  33  Yes  No  Yes  Yes  No  Q 
Le et al, 2016, 
USA 
3  Yes  No  Yes  Yes  No  Q 
Scherr et al, 2017, USA  3  Yes  No  Yes  Yes  Yes  Q/SG/CO 
Taylor et al, 2017, USA  4  Yes  No  Yes  Yes  Yes  Q 
Mader et al, 2017,  
USA 
3  Yes  No  Yes  Yes  No  Q 
Lyons et al, 2017, USA  2  Yes  No  Yes  No  No  Q 
Chen et al, 2017, 
USA 
































































































Yes  Yes  Yes  Yes  No  Yes  No  Yes  Yes  Yes  Yes  Yes  10 
Loeb et al,  
2013, Sweden 
Yes  Yes  Yes  Yes  No  Yes  Yes  Yes  Yes  Yes  Yes  Yes  11 
Filson et al, 
2014, USA 
Yes  Yes  Yes  Yes  No  Yes  No  No  Yes  Yes  Yes  Yes  9 
Hoffman et al, 
2014, USA 
Yes  Yes  No  Yes  No  Yes  No  Yes  Yes  Yes  Yes  Yes  9 
Liu et al, 
2015, USA 
Yes  No  Yes  Yes  No  Yes  No  No  Yes  Yes  Yes  Yes  8 
Maurice et al, 
2016, USA 
Yes  Yes  Yes  No  No  Yes  No  No  Yes  Yes  Yes  Yes  8 
Womble et al, 
2014, USA 
Yes  Yes  Yes  Yes  No  Yes  Yes  Yes  Yes  Yes  Yes  Yes  11 
Loeb et al, 
2016, Sweden 
Yes  Yes  Yes  Yes  No  Yes  Yes  Yes  Yes  Yes  Yes  Yes  11 
Loeb et al, 
2015,Sweden 
Yes  Yes  Yes  Yes  No  Yes  No  No  Yes  Yes  Yes  Yes  9 
Hamdy et al, 
2016, UK 








Yes  Yes  Yes  No  No  Yes  No  Yes  Yes  Yes  No  Yes  8 
Parikh et al, 
2017, USA 































































































































































































































































































































































































































































































































































































































































































































































































  Age  Occupation  Ethnicity  Marital status 
1  71  Retired garage owner  White European  Married 
2  58  Teacher  White European  Widower 
3  63  Builder  Asian  Married 
4  61  Policeman  White European  Divorced 
5  73  Retired carpenter  White European  Married 
6  49  Salesman  White European  Single 
7  66  Retired bank clerk  Black African  Married 
8  72  Property developer  White European  Divorced 
9  76  Retired bus driver  White European  Widower 
10  55  Banker  White European  Married 
11  66  Retired GP  Black Caribbean  Married 
12  66  Charity executive  White European  Partnership 
13  66  Retired factory foreman  Black Caribbean  Married 
















1  71  5.1  3+3  T2a  37 
2  58  3.9  3+4  T2a  26 
3  63  7.8  3+3  T2b  29 
4  61  3.2  3+3  T1b  31 
5  73  4.1  3+4  T2b  55 
6  49  3.1  3+3  T1b  25 
7  66  5.5  3+4  T2a  41 
8  72  5.8  3+4  T2a  63 
9  76  9  3+3  T1b  44 
10  55  2.1  3+3  T1a  38 
11  66  4.5  3+4  T2a  34 
12  66  7.2  3+4  T2b  42 
13  68  8  3+3  T2a  48 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2  Exercise advice  71  Exercise advice  43 
3  Lifestyle advice  72  Lifestyle advice  49 
4  Public role model stories  70  Public role model stories  59 
 
Table 28  Prioritisation of method of follow‐up  
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Background: Researchers remain divided on the major causes of dropout from active
surveillance (AS), with rates of up to 38% among men with no evidence of prostate cancer
(PC) progression.
Objective: To develop and evaluate an educational intervention in terms of adherence
to AS among men with low- to intermediate-risk PC.
Design, setting, and participants: We ﬁrst carried out focus group discussions with
men who had remained on and dropped out of AS to inform an intervention to increase
adherence to AS. A total of 255 consecutive men who had selected AS were then
recruited to either standard care (written information and access to a nurse specialist)
or standard care and the intervention.
Intervention: An educational seminar was designed by patients and clinicians includ-
ing information on imaging, biopsy techniques, understanding pathology, large AS
cohorts - mortality and morbidity risk and diet and lifestyle advice.
Outcome measurements and statistical analysis: The proportion of men dropping
out of AS for reasons other than disease progression was assessed at 1 and 5 yr after AS
selection using multivariate logistic regression.
Results and limitations: Common themes inﬂuencing decision-making by men on AS
were identiﬁed: (1) clinical consistency; (2) information; and (3) lifestyle advice.
Addition of an educational seminar led to signiﬁcantly fewer men dropping out of
AS: at 1 and 5 yr the dropout rate was 25% and 42%, respectively, in the standard care
group, compared to 11% and 22% (p = 0.001) in the intervention group. In the interven-
tion group, 18 men failed to attend the seminar.
Conclusions: The AS dropout rate was halved following a single educational seminar
delivered to groups of men with intermediate- or low-risk PC, even at 5 yr.
Patient summary: Men on active surveillance (AS) for prostate cancer feel more
supported when provided with an educational seminar within 3 mo of their treatment
choice. The seminar halved the number of men dropping-out of AS, even at 5 yr.
© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
* Corresponding author. Department of Uro-Oncology, The Royal Marsden Hospital, Fulham Road,
London SW6 3JJ, UK. Tel.: +44 79 58783742.
E-mail addresses: netty.kinsella@rmh.nhs.uk, jkinsella2009@hotmail.co.uk (N. Kinsella).
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euo.2018.09.007
https://doi.org/10.1016/j.euo.2018.09.007
2588-9311/© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
1. Introduction
According to European guidelines, a large proportion of men
with localised low-risk prostate cancer (LRPC) do not
require immediate treatment and can be monitored, an
approach known as active surveillance (AS) [1]. However,
international variation in determinants for safe AS inclusion
and follow-up [2] continue to contribute to high AS dropout
rates (up to 38%) among men with no evidence of disease
progression [3].
Researchers remain divided on the major causes of AS
dropout. A recent systematic review of AS choice and
adherence literature [4] reported six domains driving
unnecessary AS dropout: (1) patient characteristics; (2)
tumour characteristics; (3) family and social support; (4)
provider; (5) health care organisation; and (6) health policy.
However, studies have widely shown that informational
interventions aimed at men on AS have a favourable impact
on AS adherence. Oliffe et al. [5] found that self-management
strategies helped men to cope with some of the long-term
uncertainty of AS, while the Prostate Cancer Lifestyle trial,
based on lifestyle modifications including exercise and
attention to stress management, demonstrated an improve-
ment in treatment-free survival on AS [6]. Goh et al. [7] found
that men who perceived that they were receiving useful and
consistent information were more satisfied with and there-
fore more likely to continue on AS, whilst the UK-based
ProtecT trial [8] found merit in consistency of personnel to
support and inform patients. Interventions relating to peer
support have also yielded a significant improvement in the
quality of life of men with any stage of PC [8,9].
Here we describe the development and evaluation of an
intervention based on previous research efforts and local
focus groups that uses a standardised information and
support delivery technique with the aim of increasing AS
adherence.
2. Patients and methods
This applied research project consisted of two parts: (1) focus groups
(FGs) to understand the motivation and needs of men on AS and to
explore practicalities of an intervention to support AS adherence; and (2)
a pilot study to assess the intervention effect.
2.1. Focus groups
Permission was obtained from the local urology audit committee to
identify potential participants through electronic records (permit no.
U13887). In December 2009 and April 2010, two FGs were facilitated by
the clinical nurse specialist (CNS) team. The ﬁrst consisted of eight men
who were currently on AS and the second of seven men who had dropped
out of AS without evidence of PC progression. A semistructured question
guide was developed to provide structure for each FG (Supplementary
material) on the basis of a review of the available literature [10].
We used thematic analysis, an inductive process designed to identify
and examine emerging themes from conceptual data [11]. Thematic
saturation in qualitative data has been reported at 15 subjects in
interview studies [12] and therefore two FGs were scheduled. Purposeful
homogeneous sampling was used to provide conceptual signiﬁcance to
the question of adherence [13].
2.2. Developing the intervention
The intervention was developed in line with recommendations from the
FGs. A Powerpoint presentation was coauthored by patients, nurses, and
doctors, with ﬁnal ratiﬁcation by the AS reference group (4 partners of
and 10 men currently or previously on AS).
The proposed 1.5-h seminar included information on: imaging;
biopsy techniques; understanding pathology; the mortality and mor-
bidity risks in large AS cohorts; and diet and lifestyle advice. Optimal
seminar delivery was deﬁned as a team approach between the urologist
and CNS. Time was scheduled at the end of the seminar for questions and
peer group discussion.
2.3. Recruitment
We used a consecutive sampling method [14] appropriate to a service
improvement process in which a standard of care is evaluated before and
after an intervention. The inclusion criteria were men diagnosed with
low- to intermediate-risk PC (deﬁned using the D’Amico classiﬁcation
system [15]; Supplementary Table 1) suitable for AS on the basis of
information from magnetic resonance imaging (MRI) and transrectal
prostate biopsy with conﬁrmatory transperineal prostate biopsy. The AS
progression criteria were: Gleason score 3 + 4 (transperineal biopsy
approach, minimum of 24 cores) or where the maximum contiguous
cancer length was 6 mm, MRI ﬁnding >T2b and 30% of cores positive.
Follow-up was carried out according to National Institute for Health and
Care Excellence (NICE) guidelines (Supplementary Table 2).
Between January 2011 and June 2011, 135 men were recruited (group
A), and offered standard care [16] including introduction to a CNS and
written information on AS [17]. A second consecutive group recruited
between July 2011 and December 2011 (group B) included 120 men who
were offered standard care and participation in the educational seminar.
We compared AS dropout rates at 1 and 5 yr after diagnosis. Patient
and clinical characteristics at diagnosis and outcomes were compared
between the groups using descriptive statistics. Multivariate logistic
regression, after adjusting for age, grade, diagnostic prostate-speciﬁc
antigen (PSA), digital rectal examination (DRE), and clinical stage, was




3.1.1. Designing the intervention: FGs
The themes that emerged from the two FGs were: (1)
consistency in the clinical team, administration, and follow-
up protocol; (2) consistent information regarding PC and
AS; and (3) diet and lifestyle advice.
3.1.1.1. Clinical consistency (panels 1 and 2). In both FGs, men
described the importance of a consistent approach to
follow-up as well as familiarity with the clinical team
(Supplementary material).
Men still on AS found reassurance: “My CNS always sees
me for my PSA review, I have a great relationship with her, I
could ask her anything.”
Men in the group that had dropped out of AS described
their experience as stressful: “Nobody could give me any
guarantees about AS follow-up, every guideline seemed to be
different. It made me very nervous.” They also described
inconsistencies in the clinical team as “very difficult.”
E U R O P E A N U R O L O G Y O N C O L O G Y X X X ( 2 0 18 ) X X X – X X X2
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3.1.1.2. Consistent information (panels 3 and 4). The two FGs
differed in their response to the information given during
AS. Those who had remained on AS felt that the amount of
information given was adequate: “I was given some
information leaflets by my CNS. I thought they were very
good.” The men who had dropped out of AS described the
information as inconsistent: “Every time I saw a new doctor
or nurse I would question them about PC and AS. Sometimes
the answers were the same, other times they sounded like they
didn’t know what they were talking about.”
3.1.1.3. Diet and lifestyle advice (panels 5 and 6). Men remaining
on AS described self-help as a major contributor to their
quality of life: “I found lots of information on the internet
about diet and exercise. I changed my diet and began to go to
the gym. I think everyone who has cancer should be aware.
I’ve never felt better.”
Men who had opted out of AS suggested that: “There really
wasn’t any information on how I might help myself on AS” and
“I don’t think the nurses or doctors believed that diet, exercise,
or complimentary treatments would help on AS. I might have
stayed on AS if I’d had the opportunity to discuss this.”
3.1.2. Developing the intervention
The FGs discussed the medium through which the
information and support should be given, including a
website, bespoke written information, a webinar, and a
peer-group seminar. Men who had dropped out of AS
described their experience of websites and on-line forums
as “cold”. The men who had remained on AS felt that
websites gave no opportunity for feedback and that forums,
although interactive in some cases, were “extreme and
unpoliced.” There was universal agreement that the content
of the intervention should be empowering, with an
emphasis on self-care. Of 15 participants, 13 agreed that a
one-off peer-group educational seminar would suit the
needs of the majority, with an option to reattend when/if
required. It was suggested that the seminar should be held
within 3 mo of choosing AS to mirror the early support and
information that men undergoing radical treatment receive.
It was also suggested that the seminar content should be
similar to our programme of seminars offered to men
undergoing prostatectomy and radiotherapy [18]. Five
topics were agreed on: imaging; biopsy techniques;




A total of 273 men were recruited to the study. Eighteen
men in the intervention group failed to attend the seminar
and were therefore omitted from the final analysis. This left
255 men, 135 in group A and 120 in group B (Fig. 1).
There were no significant differences between the groups
for age, PSA and DRE clinical stage at study entry (Table 1).
Fig. 1 – Intervention trial recruitment. CNS = clinical nurse specialist.
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However, there was a significant difference in Gleason grade
group (GGG): 42 men (31%) in group A and 111 (93%) in group
B had GGG1, while 93 (69%) in group A and nine (7%) in group
B had GGG2. It was felt that this was most likely associated
with an increase in confidence for local AS monitoring
practice in the intermediate-risk PC group [19].
3.2.2. Adherence to AS
No man experienced clinical disease progression in the first
year. However, 25% in group A and 11% in group B dropped
out of AS (p = 0.003; Table 2).
By year 5, patients in group B remained less likely to drop
out of AS. The dropout rate without evidence of progression
was 21.7% in group B and 41.5% in group A (p < 0.001)
(Table 2). Owing to the difference in clinical characteristics
between the groups, the AS dropout rate due to cancer
progression at 5 yr after diagnosis was higher in group B
than in group A (21.7% vs 12.6%) [20,21].
The dropout rate remained significantly lower among
seminar participants after adjustment for baseline clinical
characteristics, including GGG, at both 1 yr (odds ratio [OR]
0.21, 95% confidence interval [CI] 0.09–0.49) and 5 yr (OR
0.26, 95% CI 0.12–0.56; Table 3). Identical results were found
when restricting the analysis to GGG1, with an OR of 0.25
(95% CI 0.11–0.53) for dropout among patients without
evidence of disease progression at 5 yr.
4. Discussion
This is the first mixed-methods study to develop an
educational supportive intervention and assess its impact
on AS adherence over a 5-yr period. Our findings demon-
strate the effectiveness of a structured, interactive,
educational seminar in increasing adherence to AS for
men with low- to intermediate-risk PC.
The needs of men requiring radical treatments for PC
have previously been examined and have helped to define
and develop the role of the CNS in supporting patients
[22]. However, less is known about the resources required
by men selecting AS or engaging in long-term AS. A recent
qualitative study suggested six requirements of men on AS
[23]: (1) general information on PC and how to interpret
results; (2) specific information on AS investigations,
follow-up, and mortality risk; (3) complementary options
regarding diet, lifestyle, and exercise; (4) a variety of
resources; (5) social support and interaction; and (6)
verification of the integrity of information. These require-
ments were reflected in our own FGs. Men who had opted
out of AS felt particularly strong about this.
4.1. The clinical team
The patient relationship with the clinical team is an
important variable in adherence to healthcare, but it is
difficult to assess the nature of this interaction and to
measure its components. Poor communication is tradition-
ally measured in terms of a patients’ inability to recall
clinician instructions, with patients failing to recall between
one-third and one-half of statements given to them
[24]. One FG participant suggested:
“The doctor didn’t even let me sit down, he greeted me at the
door and said, ‘Your PSA is fine, see you next year.’ I had
questions, I wasn’t encouraged to ask them” . . . “after
leaving the clinic I couldn’t even remember what my PSA
level was, I had to call the nurse later that same day. I was
Table 1 – Characteristics of participants in both arms of the nonrandomised intervention study
Characteristics at active surveillance entry Standard care Educational seminar p value
Patients (n) 135 120
Mean age, yr (standard deviation) 62.4 (6.8) 63.3 (7.4) 0.34
Mean prostate-speciﬁc antigen, ng/ml (standard deviation) 9.2 (7.0) 8.6 (5.3) 0.42
Gleason score, n (%)
3 + 3 42 (31.1) 111 (92.5) 0.001
3 + 4 93 (68.9) 9 (7.5)
Digital rectal examination assessment, n (%)
Benign 47 (34.8) 46 (38.3) 0.56
T2 77 (57.0) 68 (56.7)
T3 11 (8.2) 6 (5.0)
Table 2 – Active surveillance outcomes by intervention group at 1 and 5 yr
Program outcomes Patients, n (%) p value
Standard care Educational seminar
At 1 yr
Remained in the active surveillance program 101 (74.8) 107 (89.2)
Dropped out due to disease progression 0 0
Dropped out with no disease progression 34 (25.2) 13 (11.2) 0.003
At 5 yr
Remained in the active surveillance program 62 (45.9) 68 (56.7)
Dropped out due to disease progression 17 (12.6) 26 (21.7) 0.053
Dropped out with no disease progression 56 (41.5) 26 (21.7) <0.001
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told all I needed to know was that I didn’t need to worry
myself—that was it, end of conversation”.
[Participant 9, 69 yr]
Initial selection of AS is strongly associated with
multidisciplinary care [25]. However, while multidisciplin-
ary clinics are recognised as advantages in optimising AS
choice, our FG feedback suggests that variability in
personnel managing AS leads to specific concerns regard-
ing consistency. This was demonstrated through commen-
taries from several participants (panel 2; Supplementary
material).
However, it has been found that a combination of a CNS
and a doctor benefited men with PC. Tarrant et al. [26] and
Ream et al. [27] found that men who had accessed a CNS
reported a more positive experience of their cancer
management. Our FGs confirmed that a combination of
medical and nursing staff was optimal in giving information
and supporting men on AS (panel 1; Supplementary
material).
4.2. Detailed and consistent information
Information has a variety of benefits for cancer patients,
particularly in reducing anxiety, improving the ability to
cope with treatment, and in achieving better self-care.
Information can help to empower patients. Recognition of
the role that support and information play in effective
cancer care is not new. In 2002, NICE commissioned a report
on improving outcomes in urological cancers [28]. It
recognised that in PC in particular, the appropriate management
strategy may depend on an individual’s values and
attitudes, but should include: information about basic
anatomy and pathology; PC and individual variation in its
impact and rate of progression; treatment options; proba-
bility of survival; symptom reduction; risks; and potential
short- and long-term effects. Our FGs reported frustration in
this respect, describing a lack of clarity about the informa-
tion provided that appeared to extend to the medical and
nursing team (panel 4; Supplementary material).
O’Callaghan et al. [29], Oliffe et al. [5], and Davison and
Breckon [30] found that patients on AS became particularly
stressed when information given by the clinical team was
contradictory or inconsistent. Our FG participants also
agreed that there was inconsistency, describing a lack of
objective and robust information, and poor descriptors of
disease risk and AS (panel 4; Supplementary material).
The FGs discussed both the delivery method and the type
of information and support required. All agreed with a
2010 FG study that reported that information on the
internet was contradictory, limited, and difficult to find [31]
and therefore a dedicated informational source was
required.
Many of the men who had dropped out of AS and later
chose to undergo radical treatment also remarked on the
inconsistent approach to information and support services
between men offered AS and those undergoing radical
treatment.
Our group previously reported a significant increase in
patient satisfaction when men were offered access to a peer-
group educational seminar on radical prostatectomy
[18]. Galbraith et al. [32] described how this can provide
a sense of meaning in men’s experience of PC. FG
participants also suggested that mimicking the information
and support given to patients in other treatment groups
might influence the behaviour of the health professional
team by endorsing AS as a valid treatment option [4].
4.3. Diet and lifestyle advice
A 2015 systematic review of supportive care in PC
highlighted self-care in nine papers [33]. The authors
discussed the empowerment and sense of control that come
from self-care through lifestyle changes. Nanton et al. [34]
found that by “taking an active part in their own health
Table 3 – Multivariate logistic regression for the odds of dropout for reasons other than disease progression a
Parameter Odds ratio (95% conﬁdence interval)
At 1 yr By 5 yr
(n = 253) Whole cohort Excl. men with Excl. men with DP
(n = 253) DP (n = 210) and GGG2 (n = 125)
Seminar intervention
No 1.00 1.00 1.00
Yes 0.21 (0.09–0.49) 0.25 (0.12–0.51) 0.26 (0.12–0.56) 0.25 (0.11–0.57)
Age (continuous) 1.03 (0.98–1.09) 0.94 (0.91–0.98) 0.93 (0.90–0.98) 0.95 (0.90–1.00)
PSA (continuous) 0.94 (0.88–1.01) 0.96 (0.52–1.01) 0.98 (0.93–1.04) 0.97 (0.89–1.06)
GGG
GGG1 1.00 1.00 1.00 –
GGG2 0.44 (0.20–0.97) 0.49 (0.23–1.00) 0.48 (0.22–1.02) –
DRE
Benign 1.0 1.00 1.00
T2 0.88 (0.43–1.79) 0.98 (0.54–1.77) 0.93 (0.50–1.72) 0.75 (0.33–1.71)
T3 1.42 (0.41–4.91) 1.69 (0.54–5.32) 3.88 (0.96–15.7) 3.52 (0.51–24.0)
Excl. = excluding; DP = disease progression; GGG = Gleason grade group; PSA = prostate-speciﬁc antigen; DRE = digital rectal examination.
a All models were adjusted for age, grade, diagnostic PSA, DRE, and clinical stage.
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management, men were taking control of their illness.” This
was also described by Oliffe et al. [5] and O’Shaughnessy
et al. [35], who demonstrated the merits of using strategies
similar to those for men at other stages of disease
combining “living a normal life” with “doing something
extra”, such as dietary or lifestyle changes. This appeared to
increase both acceptability and adherence to AS and was
also described by our FG participants (panel 5; Supplemen-
tary material).
4.4. Study limitations
Our assignment of men to intervention and standard care
was not randomised, but occurred over consecutive time
periods as part of an audit/service improvement project in
which the intervention was the “new” standard of care. It is
not possible to exclude the influence of clinical practice that
may have occurred over this time period, such as initial
undersampling because of the experience of the biopsy
practitioner the learning curve of MRI team. This might have
contributed in part to the higher proportion of men
progressing in the intervention group despite a significantly
higher number of men with GGG1 at diagnosis.
In addition, the two comparison groups differed in GGG,
which might have influenced adherence. However, the
differences remained statistically significant, even after
adjustment for clinical characteristics such as GGG at
diagnosis. However, we were unable to adjust for other
recognised confounding factors such as marital status,
ethnicity, and education level.
Eighteen patients were excluded from the study as they
failed to attend the seminar intervention. Follow-up with
this patient group might have added value in reducing
future non-attendances.
5. Conclusions
Our study findings demonstrate that men on AS desire
consistency for staff contact, appointments, and informa-
tion. Subsequent evaluation of this intervention revealed
that a peer-group educational seminar delivered by the
clinical team in the initial months after starting AS reduced
the likelihood of dropping out of AS by 50%. With the trend
towards AS in LRPC increasing, interventions like this one
could help in reducing the upward drift in health care costs
worldwide.
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3  64  28  “Being in a dedicated active surveillance clinic – I’m not? Oh, I 
thought I was, I always see the same person”. 
4  70  54  “An explanation of the next steps of follow‐up  every time I go to clinic is really important ‐ reassuring”. 
5  66  43  “I have had a couple of appointments moved but this is 
understandable over a 4 year period”. 




7  69  33  “Access to my nurse specialist is most important to me” 
8  51  31  “Always being able to leave a message and someone getting 
back to me”. 
8  51  31  “I can often get my results over the phone which is much more convenient”. 
6  58  40  “There are some questions I need to ask a doctor. Some reassurances are needed from a doctor but some things I need 
to speak to my nurse about”. 
3  64  28  “’I get more time from my CNS, most of the time I just need 
encouragement to stay with the programme”  





































13  63  18  “I work away ‐ there should be a direct line to the admin 
team, I always went round the houses when I needed to 
change an appointment” 







15  70  12  “I never felt like I was seeing a specialist in AS. I just 
wanted someone to be interested in AS”.  
11  64  24  “Nobody could give me any guarantees about AS follow‐
ups, every guideline seemed to be different. It made me 
very nervous”.  












6  58  40  “I know that a friend of mine went to a class 
before he had his prostate out, they should do 
that for men on AS” 
7  69  33  “The PCUK website is updated all the time, it 
was a great recommendation for information” 
1  65  29  “I like asking questions when I see my team. I 
think that’s the only way you keep up to date” 
7  69  33  “I go to the support group once a month, it 
means I can speak to a nurse every month if I 
need to” 
5  66  43  “I go to the support group as well, I think the 
expert education sessions that they run are 
brilliant”. 
3  64  28  “I was given some information leaflets by my 
CNS. I thought they were very good”  

















































































7  69  33  “I changed my diet and started to swim twice a week, 
and finally felt as if I was doing something positive, 
something that would help me” 








2  71  43  “I’ve joined a cancer and complimentary therapies 
group on the PCUK forum, it’s really helped with 
advice” 










4  70  54  “My nurse had lots of advice on where to go for free 
exercise classes. I’ve joined a walking group and a 
local gym”. 


























9  69  12  “I didn’t know this was important, had I known I might 
not have stopped AS. I just felt helpless and I needed 
some control” 
11  64  24  “I think we should have been offered some education 
on this stuff. I might have felt more positive if I had 
been”. 
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Abstract: In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk 
prostate cancer (PC), however there is discordance amongst large AS cohort studies with respect to entry 
and monitoring protocols. We systematically reviewed worldwide AS practices in studies reporting ≥5 years  
follow-up. We searched PubMed and Medline 2000-now and identified 13 AS cohorts. Three key areas 
were identified: (I) patient selection; (II) monitoring protocols; (III) triggers for intervention—(I) all 
studies defined clinically localised PC diagnosis as T2b disease or less and most agreed on prostate-specific 
antigen (PSA) threshold (<10 µg/L) and Gleason score threshold (3+3). Inconsistency was most notable 
regarding pathologic factors (e.g., number of positive cores); (II) all agreed on PSA surveillance as crucial 
for monitoring, and most agreed that confirmatory biopsy was required within 12 months of initiation. No 
consensus was reached on optimal timing of digital rectal examination (DRE), general health assessment or 
re-biopsy strategies thereafter; (III) there was no universal agreement for intervention triggers, although 
Gleason score, number or percentage of positive cancer cores, maximum cancer length (MCL) and PSA 
doubling time were used by several studies. Some also used imaging or re-biopsy. Despite consistent high 
progression-free/cancer-free survival and conversion-to-treatment rates, heterogeneity exists amongst 
these large AS cohorts. Combining existing evidence and gathering more long-term evidence [e.g., the 
Movember’s Global AS database or additional information on use of magnetic resonance imaging (MRI)] is 
needed to derive a broadly supported guideline to reduce variation in clinical practice.
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Introduction
Prostate cancer (PC) is the second most common cancer 
diagnosis and the fifth leading cause of cancer mortality 
in men (1). In 2012, 1.09 million men were diagnosed 
worldwide, thus representing a substantial public health 
burden. The use of prostate specific antigen (PSA) 
testing and improvements in diagnostic procedures such 
as imaging and ultrasound guided biopsy have led to a 
significant increase in early diagnosis of localized, low-risk 
PC (LRPC), ranging from 10–80% of all men diagnosed 
with PC worldwide (1), and a subsequent decrease in PC 
mortality (2-4). 
A substantial proportion of men with LRPC do not need 
treatment with surgery or radiation, but can be carefully 
monitored—an approach known as active surveillance (AS). 
Overtreatment of LRPC is of concern, not only because 
of the physical and psychological morbidity associated 
with radical treatment, but also because of the economic 
healthcare burden (5,6). AS is considered a safe alternative 
to immediate treatment and is endorsed by national medical 
organizations and guideline groups as a viable management 
option for men with LRPC (7). 
More specifically, AS for LRPC can be defined as a 
treatment strategy of close monitoring through blood 
tests (PSA), digital rectal examination (DRE), imaging 
and prostate biopsy, with conversion to curative treatment 
if progression occurs (8,9). Large cohort studies have 
shown that with appropriate patient selection, risk of 
dying from PC in men on AS is low: 0.1% to 5.7% over 
10–15 years (Table 1). However, inconsistency in selection 
and adherence to AS remains. Studies suggest that patient 
preference (23,24), physician (25,26), family and peer 
group influence (27,28), National guidelines (29,30) and 
local practices (31,32) all influence this process. There is 
also no doubt that anxiety surrounding disease progression 
also plays a significant role (33-35) in influencing long-
term AS adherence. It is reported that cancer continues to 
cause more fear than debt, knife crime, Alzheimer’s disease 
and unemployment (36). Unsurprisingly therefore, studies 
continue to report that 1.6% to 38% of men opt out of 
AS often with no or little evidence of disease progression 
within 5 years (Table 1). 
However, in the last 10 years a trend towards AS adoption 
in LRPC has been reported by many large database studies, 
with some variation still noted between countries, practices 
and physicians (37). Most notable are the upward trends 
seen in North America, Australia and Europe. In 2015, 
Cooperberg and Carroll reviewed US trends in AS reporting 
from the US CaPSURE (Cancer of the Prostate Strategic 
Urologic Research Endeavor) database. This demonstrated 
a sharp rise in the uptake of AS, from 10% over the past 
20 years to 40% in 2010–2013 (4). This was replicated in 
Europe with the Swedish National PC Register reporting 
a rise from 40% to 74% between 2009 and 2014 (30) 
and in Australia, where the Victorian PC Registry (38) 
reported a 16% rise in AS uptake between the first half of 
2010 and second half (23.9% to 39.7%). This level (39%) 
was maintained over the following 2 years further increasing 
in 2015 up to 42.8% (39). This was also demonstrated in 
hospitals reporting on radical prostatectomy in both Canada 
and Germany. In Canada (Toronto), Louis and authors (40) 
reported a steady decline in the number of radical 
prostatectomies carried out for LRPC from 2007 (40.6%) 
to 2012 (13.6%), whilst in Germany the Martini Clinic (41) 
demonstrated a similar decrease for low-risk Gleason score 
6 cancer in 2014 (12.1%) in comparison to 52.2% in 2000. 
However, this increase is not universal. In contrast, a 
2014 survey (42) of 2,133 Japanese urologists suggested that 
26.9% reported no use of AS for LRPC and another 50.6% 
reported using AS in <5% of their patients. Moreover, only 
27% of respondents indicated that they would want to offer 
AS more frequently in the future. 
The increased use of AS seen in some countries suggests 
that the global trend towards conservative management for 
LRPC is gathering pace, however the fact that there is no 
worldwide consensus on defining favourable risk disease (43) 
in AS suggests that there is still some way to go in gaining 
universal acceptance.
This review aims to evaluate the literature describing 
contemporary AS practices worldwide and explores the 
importance of Movember’s GAP3 (Global Action Plan 
Prostate Cancer—Active Surveillance) collaborative effort 
in answering the key questions: what defines safe patient 
selection? What should the surveillance strategy look like? 
What clinical triggers are important in recommending 
radical treatment? 
Search strategy
Studies documenting AS cohorts with a minimum of 
5 years’ follow-up published before October 2017 were 
identified through a systematic search of electronic 
databases (PubMed/Medline 2000-now and Embase) using 
the following key search terms: “prostate cancer”, “active 
surveillance”, “follow-up”, “cohort”, and their relevant 
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synonyms. Cited references were searched and retrieved for 
potentially eligible publications. 
Studies of primary interest were those describing baseline 
and clinical characteristics of the study population, patient 
selection criteria, monitoring/surveillance protocol, AS 
drop-out, triggers for conversion to radical treatment and 
outcomes during follow-up (5-year studies with a median 
follow-up >18 months).
Findings
We identified 119 unique citations; of these 83 were 
excluded as review articles, commentaries, narratives, 
abstracts or where median follow-up was less than 
18 months. Full-text screening was carried out on 
36 articles, of which 23 were excluded, rendering 13 articles 
included (Figure 1—PRISMA diagram) each describing 
a unique AS cohort. Of the 13 included cohort studies 
(10-22), 6 took place in North America (10-12,14,17,21), 
5 in Europe (15,16,18,20,22), 1 worldwide (13) and 1 in 
Australia (19). 
The general demographic and follow-up characteristics 
of the published AS cohorts in this review vary considerably 
(Table 1). The average age across the studies was 65 years 
old. The number of participants studied ranged from 238 to 
2,494 men. The number of months’ follow-up ranged from 
19 to 180 months. 
The main findings in terms of AS adoption/patient 
selection, monitoring protocols and trigger points for 
intervention or re-assessment across the different AS studies 
are described below. 
AS patient selection 
Thirteen international AS programmes met our inclusion 
criteria, describing guidelines for AS patient selection 
(Table 2). These are described with respect to selection 
criteria based on the following components: (Tumour 
Nodes Metastases) TNM stage, PSA level, PSA density, 
percentage of cancer in prostate cores, number of positive 
cores and Gleason grading.
TNM stage
All cohorts agreed eligibility for AS meant clinically localised 
PC, with half of the cohorts using T2a or less, two [John 
Hopkins (11) and Goteborg (20)] opting to follow the Epstein 
criteria of T1c (in at least one arm of their cohort study). At 
the other end of the spectrum, three studies also included 
patients with T2b [(St Vincent’s, Australia (19), Canary 
PASS (21) and Milan (22)] and two cohorts men diagnosed 























n Additional records identified through 
other sources
(n=2)






Full-text articles assessed for eligibility
(n=36)
Studies included in synthesis
(n=13)
Full-text articles excluded, with 
reasons (n=23)
Narrative review (n=14)
Watchful Waiting studies (n=7)
Trial protocols (n=2)
Figure 1 Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram.
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with T2c disease [Canary PASS (21) and Milan (22)]. 
PSA level
Agreement between ten of thirteen cohorts suggested a 
PSA cut-off of 10 µg/L, the University of Toronto (17) and 
Royal Marsden (15) suggested an upper limit of 15–20 µg/L 
depending on life expectancy and age (>65 years) respectively. 
Only Goteborg (20) and Canary PASS (21) suggested an 
acceptable PSA for intermediate-risk disease of <20 µg/L. 
PSA density
PSA density was featured in five cohorts (11,13,20-22). 
However, there was no consensus, with Milan (22) 
and PRIAS (13) suggesting a cut off of 0.2 and John 
Hopkins (11), Goteborg (20) and Canary PASS (21) 
opting for a more conservative 0.15. 
Gleason grading
All included cohorts defined entry into AS as men with low-
risk disease—Gleason 3+3 or less. The Canary PASS (21) 
and Goteborg cohorts (20) defined an entry criteria for men 
with intermediate-risk disease as Gleason 3+4, whereas The 
Royal Marsden (15) suggested men over the age of 65 were 
acceptable for entry into AS with Gleason 3+4. 
Number of positive cancer cores
There was more agreement between institutions on the 
number of positive cancer cores (11 cohorts), which 
ranged between 2 and 3 cores in most cases. University 
of California San Francisco (UCSF) (12) suggested the 
number of cores should not exceed 33% of the total number 
of cores taken and the St. Vincent’s Australia (19) cohort 
criteria suggested 20% as a reasonable cut-off. 
Percentage of cancer in prostate core
Five of thirteen cohorts [Memorial Sloan Kettering Cancer 
Center (MSKCC) (10), Johns Hopkins (11), UCSF (12), 
Royal Marsden (15) and Milan (22)] agreed that no prostate 
core should contain more than 50% cancer with three 
cohorts [University of Miami (14), St Vincent’s Australia (19) 
and Canary PASS (21)] suggesting a more conservative 20–
34% (14,19). Five cohorts made no mention of percentage 
of PC in cores and therefore it is assumed this was not part 
of their selection criteria. 
Monitoring protocols (Table 3)
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PSAD, PSA density; PSADT, PSA doubling time; PSAV, PSA velocity; TRUS, trans-rectal ultrasound; MCL, maximum cancer length; ICI-SF, 
international conference on incontinence short-form.
recommend serial serum PSA measurements, DRE and 
surveillance biopsies to check for and identify indications of 
tumour progression (Table 3). 
DRE
Of the thirteen studies, DRE as part of the surveillance 
strategy played an important role in nine [MSKCC (10), 
John Hopkins (11) UCSF (12), University of Miami (14), 
Roya l  Marsden (15) ,  Univers i ty  o f  Copenhagen 
(UCPH) (18), St Vincent’s Australia (19), Goteborg (20) 
and Canary PASS (21)] with the frequency ranging from 3 
to 6 monthly. 
PSA
All studies carried out PSA testing, but again protocols 
ranged from 3 to 6 monthly.  Only MSKCC (10) 
recommended a 6-monthly free to total ratio PSA as useful. 
Prostate re-biopsy
Eleven studies carried out confirmatory biopsies within a 
year of initial diagnosis, whilst the Royal Marsden (15) cited 
acceptability within 2 years of AS initiation and ProtecT (16) 
required no repeat biopsy. All studies demonstrated 
differences in the frequency that biopsies were repeated 
thereafter. Two centres [John Hopkins (11) and University 
of Miami (12)] routinely biopsied annually, with the others 
ranging from 2–3 yearly or on clinical progression. Only 
the ProtecT study (16) did not perform routine and regular 
re-biopsy. UCSF (12) was the only institution to carry out 
regular trans-rectal ultrasound without biopsy. 
General health assessment 
Regular routine general health assessments were undertaken 
in two studies [MSKCC (10) and Canary PASS (21)], as a 
possible criterion for switching to watchful waiting (WW), 
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with only MSKCC indicating that they carried out regular 
lower urinary tract symptom assessment. Two centres 
[University of Toronto (17) and St Vincent’s Australia (19)] 
indicated that they switched patients from AS to WW at 
80 and 75 years old, respectively. 
Triggers for intervention 
At 5 years of follow-up, the proportion of men treated 
ranged from 14% to 50% across all of the studies. The 
proportion of men who developed metastatic disease was 
low across all studies, in the Johns Hopkins cohort (12) 
for example; this was recorded as 0.1% and 0.6% at 5 and 
15 years, respectively. The PC specific mortality rates were 
also low ranging from 0.2% to 5.7% (10,17) (Table 1).
Definitions of disease reclassification and progression 
differ across national guidelines and the AS cohorts 
described here are different. Many of the cohorts describe 
changes in one or multiple criteria for initiation of definitive 
treatment (Table 4). 
Pathology (Gleason score)
Amongst the 13 cohorts reviewed here,  8 studies 
[MSKCC (10), John Hopkins (11), UCSF (12), PRIAS (13), 
University of Miami (14), St Vincent’s Australia (19), Canary 
PASS (21) and Milan (22)] triggered intervention in LRPC if 
subsequent pathology was Gleason score >6. In the Canary 
PASS LRPC group radical treatment versus continued AS 
(with re-classification as intermediate-risk) were discussed as 
options. Two [University of Toronto (17) and Goteborg (20)] 
Table 4 Triggers for intervention (treatment or further characterisation)
Study Gleason score Positive cores No. (%) MCL PSAV PSADT (yr) DRE
MSKCC (10) >6 >3 >50% –
John Hopkins (11) >6 (>33% of total cores) >50% – – –
UCSF (12) >6 >2 – – <3 –
PRIAS (13) >6 ≥3 – <3 (yearly repeat biopsies) –
University of  
Miami (14)
>6 >2 Any increase 
in MCL
– – –
Royal Marsden (15) ≥4+3 (>50% of total cores) – >1 ng/mL 
per year
– –
ProtecT (16) 50% in PSA increase triggered review
University of  
Toronto (17)





≥4+3 >3 – – <3 –
St Vincents,  
Australia (19) 
>6 (>20%) >8 mm >0.75 <3 T2b
Goteborg (20) Any gleason or TNM 
upgrade 




>6 (VLRPC, LRPC), 
>3+4 (IRPC, HRPC)
>2 (≥34%) – – –
Milan (SAINT + 
PRIAS) (22)
>6 (SAINT) >20% of cores (up to 
2012), >25% cores 
[2012–2016]
>50% – <3 > T2c 
>6 (PRIAS) >2 – – <3 (where PSADT 3–10 years and 
biopsy not within 12 months—
additional biopsy indicated)
> T2c
LRPC, low-risk prostate cancer; IRPC, intermediate-risk prostate cancer; MRI, magnetic resonance imaging; MCL, maximum cancer 
length.
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suggested any pathological upgrade would trigger intervention. 
Two cohorts [Royal Marsden (15) and UCPH (18)] identified 
a Gleason score of ≥4+3 as the trigger point. Only Canary 
PASS (21) and Goteborg (20) gave a weighting depending on 
very low-risk/low risk (Gleason >3+3) or intermediate/High-
risk (Gleason ≥3+4) disease. 
Number/percentage of positive cores
Five of the thirteen studies [MSKCC (10), UCSF (12), 
PRIAS (13), University of Miami (14) and Milan (22)] 
maintained that >2 cores positive should trigger treatment, 
with the UCPH (18) extending this to >3 cores positive. 
St Vincent’s Australia (19) suggested that cancer found 
in >20% of any positive core should trigger intervention, 
whilst The Royal Marsden (15) and Johns Hopkins (11) 
suggested a higher threshold for triggering treatment: 
50% and 33% respectively. The remaining studies gave no 
indication of cut-off based on number of cores positive. 
The maximum cancer length (MCL) was variable, with two 
centres [MSKCC (10) and John Hopkins (11)] suggesting 
a cut-off of 50% and two centres suggesting more 
conservative numbers; St Vincent’s Australia (19) suggesting 
a cut-off of 8 mm of cancer and the Canary PASS 
consortium was set at ≥34%. The University of Miami (14) 
defined any increase in volume of PC and in MCL as their 
trigger for intervention.
PSA-based triggers for intervention included PSA 
doubling time (PSAD) and PSA velocity (PSAV). Only two 
studies suggested PSAV as an important trigger, The Royal 
Marsden (15) suggesting a PSAV of >1 and St Vincent’s 
Australia (19) >0.75. PSA doubling time was included in six 
studies [UCSF (12), PRIAS (13), University of Toronto (17), 
UCPH (18), St Vincent’s Australia (19) and Milan (22)] with 
a cut-off of 3 years. The Goteborg group (20) defined the 
trigger as any PSA progression.
Summary of systematic review
The thirteen AS cohorts  included in this  review 
demonstrated a wide variety of descriptions of LRPC. This 
indicates a clear lack of consensus on defining favourable 
risk disease, suitability for AS and intervention thresholds. 
Patient selection (Table 2): despite all studies agreeing that 
a clinically localised PC diagnosis was defined as T2 disease 
and the majority of studies agreeing on a PSA threshold 
of <10 µg/L and Gleason score 3+3 (3+4 in intermediate 
risk disease), there was significant inconsistency in practice 
when considering pathology (i.e., the number of acceptable 
positive cores and MCL). 
Monitoring protocols (Table 3): all studies agreed on PSA 
surveillance with a frequency ranging from 3 to 6 monthly 
and most agreed that a confirmatory biopsy was required 
within 12 months after AS selection, however, no consensus 
was reached on the importance and relevance of DRE or re-
biopsy strategy. 
Triggers for intervention (Table 4) :  the cohorts 
described here appear cautious in their definition of disease 
progression, with low tolerance for increasing PSA defined 
as “any” or number of positive cores, cancer volume, and/or 
change in Gleason score. There was no universal agreement 
on triggers for intervention although, agreement was 
reached on Gleason score >6 in 62% of studies, number of 
percentage increase in positive cancer cores was identified 
in 69% of the cohorts, MCL and PSA doubling time of 
<3 years was used in 46% of the studies. 
A narrative review performed in 2016 showed that 
existing guidelines regarding AS for PC vary widely, but 
predominantly state that the most suitable patients for 
AS are those with pre-treatment clinical stage T1c or 
T2 tumours, serum PSA levels <10 µg/L, biopsy Gleason 
scores of ≤6, a maximum of two tumour positive biopsy core 
samples and/or a MCL of 50% per core sample (44). The 
heterogeneity in practice demonstrated in this narrative, 
further highlights the need for a robust collaborative 
worldwide prospective study to finally determine safe 
patient selection, monitoring and appropriate triggers for 
intervention.
The future of AS
Imaging 
The use of magnetic resonance imaging (MRI) in the 
context of AS varies between practitioners, countries and 
healthcare systems. Current European (45) guidance on 
prostate MRI concentrates on its role in the detection 
and staging of PC. Little evidence has yet been published 
supporting more generalised use in the context of AS. 
This may explain why only two of the thirteen cohorts 
reviewed [the Milan arm of the PRIAS study (22) and 
University of Toronto] used MRI to support AS at the time 
of reporting. The Milan group used MRI imaging routinely 
(from 2015) as an adjuvant to the AS selection criteria, 
opening up AS selection to men with negative MRI scans. 
No limit was placed on number of positive cores in patients 
with negative MRI’s or where targeted biopsy shows 
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3+3 disease only. The University of Toronto used MRI as 
a conduit to triggering intervention. Where patients had a 
PSADT of <3 years, MRI and/or repeat biopsy was used to 
clarify the need for treatment. 
In 2015 a systematic review of MRI use in AS found 
only seven studies addressing MRI reliability in relation in 
selecting patients for AS using biopsy correlation and two 
studies focused on the use of repeat MRI in AS (46). This 
review was hampered by the small number of patients in 
the included studies as well as the low number of studies. It 
was concluded that MRI could detect clinically significant 
PC, however as of yet MRI cannot be considered as an 
alternative to repeat biopsy in long-term monitoring on AS 
without further evidence from robust prospective studies. 
Despite the paucity of evidence, in 2014 the UK National 
Institute for Heath and Care Excellence (NICE) PC 
guidelines (8) suggested a role for MRI in AS, but without 
any guidance on the criteria for radiological significance 
and progression. With this in mind, the European 
School of Oncology recently reported the PRECISE 
recommendations (47) for MRI usage in AS, with the aim 
of facilitating the development of a robust evidence base for 
documenting changes in prostate MRI findings in men on 
AS over time. This checklist will allow for better assessment 
of the natural history of MRI change in men on AS. 
The role of nomograms in AS
Nomograms have been successfully used and integrated 
into healthcare setting as an assist to both patients and 
clinicians in establishing risk and aiding decision making. 
There is widely accepted usage of nomograms in PC 
diagnosis (48,49). However, predictive nomograms for 
indolent disease in the context of AS have been less 
successful (50). In 2016 Venderbos and colleagues studied 
participants of the European Randomized study of 
Screening for PC (ERSPC) (51) to establish whether a 
probabilistic nomogram could improve patient selection 
for AS compared to a rule based criteria. They reviewed 
men initially diagnosed with histopathological indolent PC 
at radical prostatectomy [defined as pT2, Gleason pattern 
≤3 and tumour volume (TV) ≤0.5 mL or TV ≤1.3 mL] to 
develop an existing nomogram to provide probability-based 
data and compared this to rule-based selection according 
to the PC Research International: Active Surveillance 
(PRIAS) (13), University of Toronto (17), and Johns 
Hopkins (11) criteria. The performance of the nomogram, 
using the Johns Hopkins (11) and PRIAS (13) rule-based 
criteria’s, were found to be comparable and could prove a 
good alternative to rigid rule-based surveillance protocols 
where patients request more information on probability of 
progression to make informed decisions on treatment.
Global action plan PC active surveillance (GAP3) 
initiative 
Although AS has evolved to a broadly accepted management 
strategy for men diagnosed with LRPC, this systematic 
review of worldwide AS practices confirms there is little 
consensus on inclusion criteria, surveillance schedules and 
intervention thresholds. Also, variation in AS semantics 
used in literature and guidelines could lead to confusion.
To address these issues, the Movember Foundation 
launched within their Global Action Plan Prostate Cancer 
Active Surveillance initiative (GAP3) in August 2014 (52). 
To date, GAP3 has united as many as 25 institutions, 
hospitals and research centres from the USA, Canada, 
Australia, Singapore, Japan, Korea, UK, Ireland, the 
Netherlands, France, Sweden, Finland, Switzerland, Italy 
and Spain. The primary aim of the GAP3 initiative is to 
create global consensus on the selection and monitoring of 
men with low risk PC, ultimately resulting in worldwide 
uniform guidelines.
Within the GAP3 initiative, the largest centralized 
PC AS database to date was constructed by combining 
patient data from 25 established AS cohorts worldwide. 
This database currently comprises clinical, marker-related 
and imaging data on more than 15,000 patients. Multiple 
data analyses of this unique global data set are currently 
ongoing focussing on three main questions regarding 
AS: which patients are most suitable for AS, what is the 
most appropriate follow-up schedule and what is the right 
moment to switch to active treatment? Based on these 
results, a peer reviewed publication on consensus guidelines 
is expected in 2019.
In addition, the GAP3 programme is performing a 
centralized pathology review of randomly selected biopsies. 
Preliminary results confirm consistent biopsy quality and 
grading across the different centres, which would enable 
data analyses without correction. Moreover, a panel of 
leading PC specialists in the field of AS was convened to 
overcome the AS semantic heterogeneity in literature and 
guidelines (43). By using a modified Delphi consensus 
procedure including a three-round sequence of online 
questionnaires and a face-to-face consensus meeting, formal 
consensus was reached for all 61 individual terms.
Movember has recently allocated additional funding 
to maintain the database and update the clinical data 
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annually with a special focus on MRI, quality of life and 
genomics data. MRI is becoming an increasingly important 
technology for the management of AS. GAP3 aims to also 
assess the value of MRI with respect to lesion definition 
and changes over time. Conclusions based on the analyses 
of patient series published to date are limited due to small 
size cohorts. Therefore, the need to combine these data is 
imperative to assess the value of MRI. This also holds true 
for assessing the use of genomic markers, as well as quality 
of life in the decision to initially pursue AS rather than 
active treatment. 
In summary, analyses of global AS data within GAP3 will 
further elucidate the optimal inclusion criteria, surveillance 
schedules and intervention thresholds and result in more 
uniform AS guidelines.
This will enable clinicians to more confidently identify 
men who are suitable for AS and to also decide whose 
PCa has progressed and will, therefore, require treatment. 
In addition, this will reassure men of making the most 
informed treatment decision for their type of disease. 
Conclusions
In the last 15 years large cohort studies have progressed the 
definition of safe AS. Collaborations between institutions 
[ProtecT (UK) (16) and Canary PASS (US) (21)] and even 
countries [The PRIAS study (13)] have contributed to our 
increasing confidence in AS and a demonstrable increase in 
the number of men selecting AS. 
This systematic review shows that AS is being applied. 
However, implementation of successful AS programmes 
worldwide needs to reduce the over treatment of PC as 
well as creating a safety net for men incorrectly diagnosed 
with indolent disease. Currently, the general Urologist and/
or Oncologist may struggle to manage these patients with 
any degree of confidence, which may explain variations in 
practice. This confidence requires robust data from large 
cohorts with long follow-up, such as collected within the 
GAP3 initiative, to create global consensus on inclusion 
criteria, surveillance schedules and intervention thresholds. 
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Abstract
Context: Despite support for active surveillance (AS) as a first treatment choice for men
with low-risk prostate cancer (PC), this strategy is largely underutilised.
Objective: To systematically review barriers and facilitators to selecting and adhering to
AS for low-risk PC.
Evidence acquisition: We searched PsychINFO, PubMed, Medline 2000-now, Embase,
CINAHL, and Cochrane Central databases between 2002 and 2017 using the Preferred
Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. The
Purpose, Respondents, Explanation, Findings and Signiﬁcance (PREFS) and Strengthen-
ing the Reporting of Observational Studies in Epidemiology (STROBE) quality criteria
were applied. Forty-seven studies were identiﬁed.
Evidence synthesis: Key themes emerged as factors inﬂuencing both choice and adher-
ence to AS: (1) patient and tumour factors (age, comorbidities, knowledge, education,
socioeconomic status, family history, grade, tumour volume, and fear of progression/
side effects); (2) family and social support; (3) provider (speciality, communication, and
attitudes); (4) healthcare organisation (geography and type of practice); and (5) health
policy (guidelines, year, and awareness).
Conclusions: Many factors inﬂuence men's choice and adherence to AS on multiple levels.
It is important to learn from the experience of other chronic health conditions as well as
from institutions/countries that aremaking signiﬁcant headway in appropriately recruiting
men to AS protocols, through standardised patient information, clinician education, and
nationally agreed guidelines, to ultimately decrease heterogeneity in AS practice.
Patient summary: We reviewed the scientiﬁc literature for factors affectingmen's choice
and adherence to active surveillance (AS) for low-risk prostate cancer. Our ﬁndings
suggest that the use of AS could be increased by addressing a variety of factors such as
information, psychosocial support, clinician education, and standardised guidelines.
© 2018 European Association of Urology. Published by Elsevier B.V. All rights
reserved.
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1. Introduction
Prostate cancer (PC) accounts for 400 000 new cancer cases
in Europe [1] and 160 000 in the USA [2] annually. Rapid
uptake of prostate-specific antigen (PSA) testing and better
diagnostic procedures have led to a significant stage
migration with earlier diagnosis of localised, low-risk PC
(LRPC), ranging from 10% to 80% of all men diagnosed with
PC worldwide [3–5]. A large proportion of these men do not
require immediate radical treatment, but can be monitored
using blood tests, digital rectal examination, prostate biopsy
and/or multiparametric magnetic resonance imaging
(MRI)— an approach known as active surveillance (AS) [5].
While there are no universally agreed upon selection
criteria for AS, the authors of a recent review of currently
used guidelines worldwide agreed on the following criteria,
consistent with the definition of very LRPC: clinical stage
T1c–T2a, PSA<10 ng/ml, biopsy Gleason score 6, maximum
1 or 2 positive biopsy cores, and/or maximum 50% of cores
with cancer [6].
Large cohort studies (Supplementary material, Overview
of large cohort active surveillance studies) reporting over
the last 5 yr have shown little physical morbidity and low
PC-specific mortality while on AS: 0.1–5.7% over 10–15 yr
[7,8], observations that have recently contributed to an
increased uptake of this management strategy [5,9].
AS uptake continues to vary across countries and practices,
and among physicians [10]. This was most noticeable in the
US Cancer of the Prostate Strategic Urologic Research
Endevour (CaPSURE) database, which reported a sharp rise
in the uptake of AS, from10% over the past 2 decades to 40% in
2010–2013 [5], and the Swedish National Prostate Cancer
Register (NPCR), which noted a rise from 40% to 74% between
2009 and 2014 [11]. In Australia, where the healthcare culture
is fairly evenly split between private and public systems, a
25% overall recruitment to AS was recorded by the Victorian
PC Registry during the period 2008–2012 [12]. However, in
Sweden, where healthcare is delivered largely by the public
sector, the proportion of men selecting AS was significantly
higher (80–90% of eligible men) [11]. Understanding the
drivers for this variation in practice is essential.
In cohort studies reporting on AS adherence, a large
proportion of men continue to drop out of AS, despite no
evidence of disease progression (Supplementary material,
Overview of large cohort active surveillance studies). Much
research has focused on the influence of anxiety and
depression on adherence. Cancer Research UK describes
depression as an established response to a diagnosis of
cancer, unrelated to stage or severity [13]. However, in PC
the risk of moderate to severe depression (requiring
treatment) has been reported as relatively low in compari-
son with other tumour groups, at 5% [14].
There is thus a need to identify and understand the
barriers and facilitators to AS. This would then provide
means for future research themes to study interventions
aimed at increasing both uptake of and adherence to AS. The
purpose of this paper is, therefore, to systematically
evaluate the literature for factors affecting choice and
adherence to AS as a PC management strategy for LRPC.
2. Evidence acquisition
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
guidelines [15].
2.1. Search strategy
Studies published between 2002 (when AS was first
described in the literature [16]) and December 2017 were
identified through a systematic search of electronic
databases (PsychINFO, PubMed, Medline 2000-now,
Embase, CINAHL, and Cochrane Library; Fig. 1). The search
strategy focused on the use of keyword search terms to
identify studies based on PC AS: prostate cancer OR
prostatic neoplasm, active surveillance OR watchful wait-
ing, facilitators OR barriers, treatment adherence OR
treatment compliance, treatment OR therapy OR therapeu-
tics, and decision making. The full search strategy is
identified in Figure 2. References were also searched for
eligible publications.
2.2. Study eligibility and selection
Eligible studies for inclusion in the final analysis were those
that evaluated choice and/or adherence to AS rather than
watchful waiting (WW). Although there are similarities
between choice of AS and WW, they are conceptually
different management strategies (AS is a strategy employed
tomonitor a patient where there is intention to offer radical
treatment with curative intent when/if required; WW
implies no intention to offer curative treatment). Hence,
studies where AS and WW subgroups were combined were
excluded to reduce bias.
We considered studies eligible if they were original
articles with a qualitative or quantitative design generating
data on decision making in LRPC when AS was considered a
primary treatment option. Eleven studies were excluded on
the basis of poor study quality or mixed WW/AS subgroup
[17], as were qualitative studies that failed to state that
saturation of information had been reached (usually 20
participants). Inclusion of at least 20 participants in a study
is a general guideline in qualitative research to reach data
saturation [18]. One study that fell beneath this threshold
was included as information saturation was demonstrated.
Cohort/registry studies were included when they were
multi-institutional and included >500 patients to reduce
the associated risk of bias in small sample sizes and increase
the external validity and generalisability. Studies reporting
on AS adherence also included 2 yr of follow-up.
2.3. Data quality
Qualitative andmixed-methodology studieswere evaluated
for quality using the Purpose, Respondents, Explanation,
Findings and Significance (PREFS) quality checklist[1_TD$DIFF]. This
checklist was [2_TD$DIFF] developed by [10_TD$DIFF]Joy [11_TD$DIFF]and [12_TD$DIFF]Bridges [17] for
assessing quality of reports in systematic reviews of
literature on patient preferences and comprises questions
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regarding five aspects of each study: purpose (P), respon-
dents (R), explanation (E), findings (F), and significance (S).
The complete PREFS checklist is shown in Table 1. The PREFS
checklist in the Supplementarymaterial outlines the quality
questions. A quality score was calculated by adding one
point for each “yes” answer on the PREFS checklist, with a
maximum potential score of 5. Papers were categorised in a
way similar to that reported by Joy et al [17]: standard
gamble (SG, ie, health-related quality of life [HRQoL])—17
papers; contingent evaluation (CO; ie, survey)—14 papers;
stated preference other (SPO; ie, monetary value or choices
or ratings)—three papers; qualitative (ie, interviews)—13
papers; and three papers with mixed methodology.
The mean PREFS quality score was 3.46 (standard
deviation [SD] 0.54), and the scores ranged from 2 to
5. The mean quality scores were 3.15 (SD 0.55) in studies
with qualitativemethods, 3.33 (SD 0.57) in studies with SPO
methods, 3.76 (SD 0.44) in studies with CO methods, 3.58
(SD 0.51) in studieswith SGmethods, and 3 (SD 0) in studies
with mixed methodology. Forty-six studies explicitly stated
that the purpose (P domain) of the study was to evaluate
factors effecting choice or adherence to AS, and 31 studies
[(Fig._1)TD$FIG]
Fig. 1 – Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram. AS = active surveillance; NA = not available.
[(Fig._2)TD$FIG]
Fig. 2 – Search strategy.
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included all respondents in the evaluation of findings (F
domain). There was more variability among the studies in
satisfying the R, E, and S domains of the PREFS checklist,
demonstrating that many reports lacked details regarding
whether responders were similar to nonresponders and
failed to include statistical tests to evaluate results where
possible.
The included cohort/registry epidemiology papers were
assessed for strength of evidence. Although no quality
assessment tool completely fitted the purpose of this
review, assessments were made using a modified Strength-
ening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) checklist [19] (Table 2). The following items
were assessed: number of participants, variables (clear
explanation of all outcomes, exposures, potential confoun-
ders, and effect modifiers), data source (details given of
measurement), bias (effort made to address potential
sources of bias), statistical methodology (description of
methods, missing data addressed, and sensitivity analysis
performed), descriptive data (characteristics of individuals
given: demographic, clinical, and social), and limitations
(generalisability addressed and cautious interpretation). In
each of the seven categories, one point was assigned to each
positive response, giving a possible total score of 12.
Table 1 – Purpose, Respondents, Explanation, Findings, and Significance checklist
Study (publication date), place Quality
score
Purpose (P) Respondents (R) Explanation (E) Findings (F) Signiﬁcance (S) Category of paper
Davison and Breckon (2012) [32], Canada 4 Yes Yes Yes No Yes CO
Goh et al (2012) [50], USA 3 Yes Yes Yes No No CO/Q
Orom et al (2014) [51], USA 4 Yes Yes Yes No Yes CO
Xu et al (2016) [ [7_TD$DIFF]27], USA 4 Yes Yes Yes No Yes CO
Orom et al (2017) [33], USA 4 Yes Yes Yes No Yes CO
Anandadas et al (2011) [25], UK 3 Yes Yes No No Yes SG
Gorin et al (2011) [41], USA 3 Yes No Yes Yes No CO
Loeb et al (2017) [52], USA 3 Yes No Yes Yes No Q
Volk et al (2014) [40], USA 3 Yes Yes Yes No No Q
Xu et al (2012) [45], USA 3 Yes No Yes Yes No Q
O’Callaghan et al (2014) [46], Australia 3 Yes No Yes Yes No Q
Mishra et al (2013) [47], USA 3 No No Yes Yes Yes SPO
Ehdaie et al (2017) [44], USA 4 No Yes Yes Yes Yes SPO
Venderbos et al (2015) [82], The Netherlands 4 Yes No Yes Yes Yes SG
Venderbos et al (2017) [67], Europe 4 Yes No Yes Yes Yes SG
Lang et al (2017) [31], USA 4 Yes No Yes Yes Yes CO
Kendel et al (2016) [79], Germany 4 Yes Yes Yes No Yes CO
Vasarainen et al (2012) [65], Helsinki 4 Yes No Yes Yes Yes SG
Bellardita et al (2013) [60], Italy 4 Yes No Yes Yes Yes SG
Vanagas et al (2013) [66], Lithuania 3 Yes No Yes No No SG
Hegarty et al (2008) [61], USA and Ireland 3 Yes No Yes Yes No SG
Smith et al (2009) [79], Australia 3 Yes No Yes Yes No SG
Parker et al (2016) [63], USA 4 Yes Yes Yes No Yes SG
Punnen et al (2013) [14], USA 4 Yes Yes Yes No Yes SG
Lane et al (2016) [75], UK 4 Yes Yes Yes No Yes CO
Van den Bergh et al (2010) [71], The Netherlands 4 Yes No Yes Yes Yes SG
Xu et al (2011) [81], USA 4 Yes No Yes Yes Yes Q
Xu et al (2016) [ [7_TD$DIFF] 8], USA 4 Yes Yes Yes No Yes CO
Wilcox et al (2014) [62], Australia 4 Yes No Yes Yes Yes SG
Burnet et al (2007) [72], UK 4 Yes No Yes Yes Yes SG
Davison and Goldenberg (2011) [73], Canada 3 Yes No Yes No No CO
Anderson et al (2014) [74], Australia 3 Yes Yes No No Yes SG
Oliffe et al (2009) [59], Canada 3 Yes Yes No yes No CO
Berger et al (2014) [85], USA 3 Yes Yes No No Yes Q
Seiler et al (2012) [86], USA 4 Yes No Yes Yes Yes CO
Kinsella et al (2015) [88], UK 3 No Yes No Yes Yes SPO
Wade et al (2015) [[8_TD$DIFF]48], UK 3 Yes No Yes Yes No CO/Q
Kazer et al (2011) [[9_TD$DIFF]55], USA 4 Yes No Yes Yes Yes Q
Wade et al (2013) [49], UK 3 Yes No Yes Yes No SG
Wade et al (2015) [[8_TD$DIFF] 9], UK 3 Yes No Yes Yes No Q
Latini et al (2007) [80], USA 4 Yes Yes No Yes Yes CO
Jeldres et al (2015) [64], USA 3 Yes No Yes No Yes SG
Donovan et al (2016) [68], UK 4 Yes No Yes Yes Yes SG
Loeb et al (2017) [83], USA 33 Yes No Yes Yes No Q
Le et al (2016) [43], USA 3 Yes No Yes Yes No Q
Scherr et al (2017) [53], USA 3 Yes No Yes Yes Yes Q/SG/CO
Taylor et al (2016) [28], USA 4 Yes No Yes Yes Yes Q
Mader et al (2017) [42], USA 3 Yes No Yes Yes No Q
Lyons et al (2017) [56], USA 2 Yes No Yes No No Q
Chen et al (2017) [69], USA 4 Yes Yes Yes Yes No CO
CO = contingent evaluation (survey); Q = qualitative (interviews); SG = standard gamble (health-related quality of life); SPO = stated preference (other) –
(monetary value or choices or ratings).
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The mean quality score was 8.78 (SD 1.8). The scores
ranged from 5 to 11. All studies included outcome variables,
a full description of statistical methodology, clinical data,
and limitations. The highest level of variability was found in
relation to bias, missing data, and sensitivity analysis. Five
papers scored 10.
3. Evidence synthesis
We identified 1049 unique citations; of these 901 were
excluded as review articles, commentaries, or narratives.
Full-text screening was carried out on 148 articles, of which
85 were excluded, rendering 64 articles included for
synthesis. Given the heterogeneous study designs, no
statistical comparisons were made.
This mixed-method systematic review uses a modified
version of the Joanna Briggs Institute—Methodology for JBI
Mixed Methods Systematic reviews (integrated approach)
[20]. Joanna Briggs Institute integrated methodology
combines both qualitative and quantitative data into a
single mixed-method synthesis [20]. A meta-aggregation of
data is presented using a Bayesian approach, whereby all
data were codified into themes and then presented in a
meta-aggregation. This approach generates summative
statements of the evidence to equally inform the topic in
a mutually compatible format [21], as seen in Table 2. The
six themes identified were as follows: cancer character-
istics, patient, family and social support, provider, health-
care organisation/practice, and health policy.
Three authors (N.K., M.V.H., and S.C.) independently
screened all titles and abstracts. The resulting reference list
was compiled for full-text screening and data extraction.
The final reference list was screened and agreed by all
authors. A data abstraction form was developed for both
qualitative and quantitative studies, based on review of the
first articles of each type from among the selected papers.
One author (N.K.) extracted data onto a spreadsheet, which
was checked by two other authors (S.C. and M.V.H.). Data
abstraction was performed separately by two reviewers (N.
K. and S.C. or M.V.H.). Data extraction included publication
year, authors, journal name, title, study design, setting,
population, eligibility criteria for participants, data collec-
tion method, response rate, and outcomes (Table 1). The
review of findings/themes was open ended with no
prespecified coding system, with intent to describe the
primary conclusions of the authors.
3.1. Study design of included studies
Table 3 summarises the 64 included studies. Thirty-seven
studies took place in North America, 20 in Europe, and five
in Australia; one compared America with Ireland; and one
was a worldwide study. The total number of study
participants was 452 4560, ranging from 7 to 189 768 in
each study. The average age at diagnosis across the studies
was 65 yr.
The assessments were reported between 2007 and
2017. The studies consisted of 13 surveys, 12 qualitative
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Table 3 – Overview of the studies included in the systematic review on factors affecting choice and adherence to active surveillance in men with low-risk prostate cancer











2012 [32] Cross-sectional survey to AS patients 180/258 (70%) Canada Clinical/hospital Survey (Likert scale) 2009–2011 67





3 Orom et al 2014 [51] Cross-sectional survey to AS patients 120/126 (79%) USA Clinical/hospital Survey 2010–2012 65
4 Xu et al 2016 [27] Cross-sectional survey to patients with localised PC 260/559 (68%) USA Population database Survey 2009–2010 61
5 Orom et al 2017 [33] Prospective survey of patients undergoing AS/RP/RT 1531/3337
(46%)










7 Gorin et al 2011 [41] Prospective survey to AS patients 105/185 (57%) USA Clinical/hospital Survey Unknown 66





9 Volk et al 2014 [40] Qualitative interviews with AS patients and RP/RT patients 30/36 (83%) USA Clinical/hospital Interviews (thematically
analysed)
2011 63





11 O’Callaghan et al 2014 [46] Qualitative interviews
with patients with
LRPC and their partners




Interviews (thematically analysed and inter-rated) 2012–2013 Range 61–70
12 Aizer et al 2012 [22] Retrospective cohort/registry study 701 USA Clinical/hospital Database Unknown 62
13 Loeb et al 2013 [24] Retrospective cohort/registry study 57 713 Sweden Population database Database 1998–2011 65
14 Filson et al 2014 [37] Retrospective cohort/registry study 7347 USA Population database Database 2004–2007 66+
15 Hoffman
et al
2014 [34] Retrospective cohort/registry study 12 068 USA Population database Database 2006–2009 66






2015 [35] Retrospective cohort/registry study 189 768 USA Population database Database 2010–2011 Unknown
18 Womble
et al




19 Loeb et al 2017 [11] Retrospective cohort/registry study 32 518 Sweden Population database Database 2009–2014 67
20 Mishra et al 2013 [47] Content analysis of patient's Internet conversations 464 USA Internet conversations Qualitative software
(sentiment index)
2002–2012 Unknown
21 Ehdaie et al 2017 [44] Prospective counselling intervention to physicians 5 surgeons;
1003 patients
USA Clinical/hospital Database and survey 2014–2015 60
22 Venderbos
et al
2015 [82] Retrospective survey comparing anxiety and distress at 0,
9, and 18 mo on AS
150 (86%, 90%,









2017 [67] Retrospective survey comparing HRQoL in treatment
groups: AS, RP, RT to matched patients



































Table 3 (Continued )








24 Loeb et al 2015 [29] Retrospective cohort/registry study 11 726 Sweden Population database Database 2003–2007 64
25 Lang et al 2017 [31] Prospective survey to AS patients 531 USA Clinical/hospital Survey 2011–2012 Unknown
26 Hamdy
et al
2016 [30] Prospective cohort/registry study 1643 UK Clinical/hospital Survey/database 1999–2009 61
27 Kendel et al 2016 [79] Prospective survey study—men on AS and RP 316 Germany Clinical/hospital Survey 2008–2013 67
28 Vasarainen
et al





2013 [60] Prospective cohort/registry study. HRQoL and database AS
adjustment analysis







2013 [66] Prospective survey study. HRQoL, anxiety, and depression
among AS, RP, RT, chemo, and HT
61/650 Lithuania Clinical/hospital Survey (EORTC, QLQ-C30) 2010–2011 >64
31 Hegarty
et al
2008 [61] Retrospective survey of men on AS—to assess differences in




Clinical/hospital Survey (MUIS-C, UCLA-PCI,
QLI)
Unknown 76
32 Smith et al 2009 [70] Retrospective cohort registry survey assessing AS HRQoL and
cancer-related data 3 yr into an AS pathway
200/1647 Australia Clinical/hospital Survey/database (SF-12,
IPSS)
2000–2002 63
33 Parker et al 2016 [63] Prospective cohort survey assessing HRQoL and anxiety in AS 180 USA Clinical/hospital Survey (EPIC, SF-12) 2006–2012 67
34 Punnen
et al
2013 [14] Prospective cohort survey, assessing differences between
RP and AS (at 1 and 3 yr) in respect to HRQoL, anxiety, and
depression.
122/679 USA Clinical/hospital Survey (PHQ-9, GAD-7) 2007–2010 60
35 Lane et al 2016 [75] Prospective cohort survey study, assessing HRQoL in AS,
RP, RT
1438 UK Clinical/hospital Survey 1999–2009 61
36 van den
Bergh et al
2010 [71] Prospective cohort survey study (PRIAS) assessing
progression, HRQoL, anxiety, depression, and patient
factors between men on AS, RP, and RT
129/150 The
Netherlands
Clinical/hospital Survey (CES-D, STAI, SF-12) 2007–2008 65
37 Xu et al 2011 [81] Qualitative interviews with patients with LRPC 7 black men,
14 white men
USA Clinical/hospital Qualitative interview
(thematically analysed)
Unknown Unknown
38 Xu et al 2016 [78] Retrospective cross-sectional survey 266/391 (68%) USA Clinical/hospital Survey 2009–2010 75
39 Wilcox et al 2014 [62] Prospective survey of men on AS—assessing HRQoL,
anxiety, and depression
47/61 Australia Clinical/hospital Survey (IIEF-5, IPSS, MAX-
PC, UAS)
2013 62
40 Burnet et al 2007 [72] Prospective survey study assessing anxiety and depression
in men on AS




2011 [73] Retrospective survey study to assess the support and
information men require to sustain them while on AS





2014 [74] Prospective cohort survey study to assess anxieties in men
with AS and determine which of these anxieties predicted
HRQoL
86 Australia Clinical/hospital Survey (HADS MAX-PC,
FACT-P, STAI)
Unknown 66
43 Oliffe et al 2009 [59] A prospective survey study to describe the range of men's
self-management strategies used to overcome AS-related
uncertainty
25 Canada Clinical/hospital Survey Unknown Unknown
44 Berger et al 2014 [85] Retrospective interview study to generate hypotheses about
the factors that inﬂuence patients’ decisions to leave AS
14/1159 USA Clinical/hospital Qualitative interviews
(thematically analysed)
2010–2013 Unknown
45 Seiler et al 2012 [86] Prospective cross-sectional survey study, to assess
differences in anxiety and depression among couples
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2015 [93] Retrospective registry study to determine the number of




Population database Database/registry Unknown 66
48 Wade et al 2015 [48] A prospective cohort survey study assessing nurse-led AS
clinics for accessibility, ﬂexibility, and level of support





2015 [12] Retrospective registry study 1603 Australia Population Registry 2008–2012 66
50 Kazer et al 2011 [55] Focus group analysis of the needs of men on AS 7 USA Research Focus group 2009–2010 70
51 Wade et al 2013 [49] Prospective/retrospective survey study 1144 (88–95%)
at 7 and 35 d
after biopsy
UK Clinical/research Survey (HRQoL, HADS) 2006–2008 62
52 Wade et al 2015 [89] In-depth semistructured interviews at 10 and 18 wk after
biopsy
85 UK Clinical/research Interviews (thematically
analysed)
2006–2008 64




54 Jeldres et al 2015 [64] A prospective cohort survey using validated HRQoL
questionnaires







2016 [68] A prospective cohort survey using validated questionnaires
to assess PROMs – HRQoL to compare men choosing
surgery versus radiotherapy versus active monitoring




56 Parikh et al 2017 [36] Retrospective cohort/registry study using the National
Cancer Database to determine patterns of AS uptake
40 839 USA Clinical/hospital Registry 2010–2013 61 (CI),
63 (AS)
57 Loeb et al 2017 [83] A qualitative study with patient focus groups and
semistructured interviews with providers, to understand
the informational needs of men on AS and inﬂuences on
provider decision making








2016 [92] A retrospective cohort review of hospital charts to assess
the impact of biopsy complications on rebiopsy
1164 Worldwide Clinical/hospital Review of hospital charts Unknown Unknown
59 Le et al 2016 [43] In-depth close-ended questions and semistructured
telephone interviews, to assess decision-making processes
by men and their partners in respect to AS and CI




60 Scherr et al 2017 [53] A retrospective review of hospital charts, structured
interview questions, prospective Likert scale survey, and
HRQoL-validated tools




61 Taylor et al 2016 [28] A prospective longitudinal cohort study of telephone
interviews before treatment to assess inﬂuences on
treatment decision preferences
1140 USA Clinical/hospital Interviews 2012–2014 61.5
62 Mader et al 2017 [42] Retrospective patient semistructured interviews assessing
choice factors in AS
15 USA Clinical/hospital Interviews Unknown 65
63 Lyons et al 2017 [56] A retrospective interview study on cognitive and affective




USA Clinical/hospital Interviews Unknown 65
64 Chen et al 2017 [69] A prospective cohort survey using a validated
questionnaire to assess HRQoL
314/1141 USA Clinical/hospital Survey (prostate cancer
symptom indices)
2011–2013 67
AS = active surveillance; HRQoL = health-related quality of life; HT = hormone therapy; IPSS = International Prostate Symptom Score; LRPC = low-risk prostate cancer; NA = not available; PC = prostate cancer;































content analysis, one intervention study, and seven mixed-
method studies. Seventeen studies reported HRQoL and/or
psychological assessment data using validated question-
naires/tools (Supplementary material, Validated tools).
Some overlap in studies was noted with eight of
64 studies reporting on factors influencing both AS choice
and adherence.
3.2. Results
This review has been split into two sections: barriers and
facilitators to AS selection and to AS adherence. These have
further been synthesised and these demonstrate influence
on six different levels: cancer characteristics, patient
factors, family and social support, provider, organisation
and practice, and health policy. The sections below discuss
facilitators and barriers according to these levels.
3.2.1. Barriers and facilitators to AS selection
3.2.1.1. Cancer characteristics
3.2.1.1.1. Facilitators. Nine studies described how cancer
characteristics such as PSA, number of positive cores,
Gleason score, and tumour volume influenced the selection
of patients for AS. A low Gleason score and a low PSA value
were identified as facilitators of AS in five of these studies
[11,22–25]. Five studies [22,23,26–28] also suggested that
tumour volume played an influential role in AS selection,
with lower volume associated with higher levels of AS
selection.
3.2.1.1.2. Barriers. The UK-based Prostate Testing for Cancer
and Treatment (ProtecT) study, USA-based CEASAR study,
and Swedish NPCR [29–31] found that men with higher
PSAs and tumour staging were disinclined to choose AS
when diagnosed.
3.2.1.2. Patient level
3.2.1.2.1. Facilitators. [13_TD$DIFF]Seven studies [26,28,32–36] indicated
that older menwere more likely to choose AS than younger
men, but were in general less engaged in the decision-
making process than younger men [32]. Comorbidity was
featured in seven studies [11,22,24,33–35,37]. The Surveil-
lance, Epidemiology and End Results (SEER) registry
reviews [34,37], the US National Cancer Database (NCDB)
[[14_TD$DIFF]34], Swedish studies [11,24], a US multidisciplinary clinic
study [22] based in Boston, and the Michigan MUSIC study
[23] showed an association between a higher Charlson
comorbidity index and choice of AS. Orom et al [33],
however, found that the presence of cardiovascular disease
was associated with a greater likelihood of choosing
radiation over AS. Both Orom et al's [39] and Parikh
et al's [36] studies suggested that men with more years of
education were more willing to opt for AS; however,
another study suggested that higher educationwas a barrier
to AS choice [24].
Six studies [25,32,40–43] suggested that fear of side
effects (in particular, erectile dysfunction and incontinence)
following radical treatment was a strong determinant of AS.
Ehdaie et al [44] found that significantly more men opted
for AS (12%) if during treatment counselling they had
proactively been encouraged not to ignore potential harms
of treatment.
3.2.1.2.2. Barriers. Nine studies showed that younger men
were less likely to choose AS. Three studies [32,33,45] found
that men younger than 60 yr were less likely to choose AS.
One comment from a patient in a qualitative interview was
“choosing AS would be irresponsible, ridiculous even at my
age (aged 53)”.
Other studies reported patient-related factors including
ethnicity and family history of PC. Aizer et al [22] suggested
that family history of PC increased the likelihood of early
dropout from AS; this is consistent with Volk et al's [40]
interview findings that twice as many patients who opted
for primary curative treatment had a relative with PC,
compared with patients who opted for AS. Xu et al's [27]
study showed that black men, as compared with white,
were less likely to choose radical treatment and specifically
surgery, due to the high risk of adverse effects. In contrast,
Orom et al's [33] survey suggested a racial difference in the
use of AS, with a higher proportion of black men choosing
radiotherapy over AS.
The association between the level of education and AS is
inconsistent: the Prostate Cancer Database Sweden
(PCBaSe) [24] suggested that a higher level of education
precipitates lower use of AS in the LRPC group (26% of men
vs 39% with a midlevel education and 35% with a lower
education level).
The psychological burden of AS with respect to the
associated repeat testing during AS [46,47], as well as the
morbidity from repeat prostate biopsies [25], was also
linked to reduced uptake of AS. Wade et al [48,49] found
that men who were well informed about prostate biopsy
were less likely to refuse repeat biopsy. This is important to
acknowledge in the context of AS where monitoring
includes regular rebiopsy. However, several studies have
described the process of repeat testing on AS as a reassuring
process [40,42,46].
3.2.1.3. Family and social support
3.2.1.3.1. Facilitators. In all the interview studies, men on AS
described justifying their decision to others as one of the
most difficult aspects of the decision-making process. Both
Xu et al [45] and Goh et al [50] reported that AS referred to
as “no treatment” was often more challenging for the
spouse and children to understand than for the patient.
Successful reassurance and education of the family were
highlighted as key facilitators to patients choosing and
adhering to AS [40,45,46].
Four interview studies from the USA, UK, and Canada
[25,32,40,46] showed that “avoidance of treatment side
effects”, “more convenient for lifestyle”, and a “combination
of reasons” were recurring themes explaining the choice of
AS. The UK study [25] also showed that men were as
satisfied with their decision to undertake AS as those who
had undergone radical treatment 2 yr later.
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3.2.1.3.2. Barriers. Pressure from family and friends has been
found to be high at the point of diagnosis, many of whom
urged curative treatment [45,47]. To give an example, in
qualitative interviews performed by Xu et al [45], one man
stated that he initially preferred AS plus nutrition supple-
ments to avoid treatment-related side effects, but that his
family pressured him to choose radical prostatectomy (RP),
and as a compromise, he finally chose radiation. In another
example, one man stated that he felt unspoken pressure
from his family to choose curative treatment.
Perception and acceptance of AS requires careful
management. Orom et al's [33] 2017 survey described that
high levels of distress at the time of diagnosis and at the
time of the treatment decisionwere predictors for choosing
RP over AS. In contrast, Xu et al [27] found that black men
were more likely to report higher levels of “cancer worry”,
but that their perception of the negative effects of radical
treatment often led to fewer men choosing radical
treatment.
3.2.1.4. Healthcare provider level
3.2.1.4.1. Facilitators. Eleven of the reviewed studies sug-
gested that the clinician heavily influences the decision-
making process [26,32,33,41,44,46,47,50–53]. Scherr et al
[53], Liu et al [26], and Davison and Breckon [32] all found
that the diagnosing urologist was the most influential
clinician associated with AS choice. Orom et al's [51]
2014 survey found that a poor relationship between
patient and clinician was mentioned by only 1% of men
whowere appropriately recommendedAS for LRPC, but by
as many as 53% of men who were recommended a
definitive treatment only.
Loeb et al [52] found that clinicians were concerned
about the burden of intensive monitoring and that they
might miss disease progression. However, both Orom et al
[51] and Loeb et al [52] found that shared decision making
would address this.
Health literacy is defined as an “individual's capacity to
access, understand, communicate, evaluate, utilise, and
make decisions based on health information” [54]. There-
fore, provision and access to relevant information are a
consistent theme in both increasing the uptake of and
adherence to AS. Mishra et al [47] described the views of
patients and their families in Internet conversations over a
10-yr period; they found that access to unbiased informa-
tion was associated with more patients opting for AS. Four
other studies [32,40,42,46] reported similar results. Goh
et al [50] found that men who perceived that they were
receiving consistent information felt more in control of
their decision making, and experienced a greater degree of
satisfaction and certainty in choosing AS. Three other
studies concluded that access to educational resources, in
addition to professional and peer support (supported self-
management), optimised the treatment selection process
and empoweredmen “to take control” of their diagnosis and
their choices thereafter [42,47,55]. However, in contrast,
Taylor and colleagues [28] found that even when patients
had access to information and support, menwho choose AS
were less likely to access these resources than those
choosing radical treatment.
A US multidisciplinary clinic study [22] found that AS
selectionwas further facilitated through amultidisciplinary
provider approach, removing the bias of treatment recom-
mendation, which is often associated with clinicians who
carry out a particular treatment. Patients receiving treat-
ment counselling from two or more specialist clinicians
were twice as likely to opt for AS than radical treatment
(43% vs 22%). This was further confirmed and described
during semistructured interviews by Lyons et al [56].
Ehdaie et al [44] further found that a systematic
approach for communicating the merits of AS using
appropriate framing techniques increased the proportion
of patients selecting AS (69% before intervention to 81%
afterwards), equating to a 30% relative reduction in
unnecessary curative treatment.
Several studies have also reported that by slowing down
the treatment decision-making process, providers might
influence an increase in the proportion of men choosing AS
[46,47,56]. Volk and colleagues [40] found significance in
men viewing their cancer as “low risk” as it offered an
opportunity to postpone treatment, allowing sufficient time
for technological advances in treatment. Based on their
answer to the question whether men chose AS as a holding
mechanism only or as a long-term solution, patients were
fitted into two groups: those who concluded that selection
of ASmeant avoidance of side effects and thosewho felt that
AS gave them time to make a treatment decision.
3.2.1.4.2. Barriers. Conversely, the clinician's influence has also
been listed as a barrier for choice of AS. Mishra et al's [47]
review of the changing trends in Internet conversations
over a 10-yr period suggested that patients were increas-
ingly receptive to considering AS, but many questioned if
physicians could provide an unbiased treatment recom-
mendation. This concern was also articulated in four of the
interview studies [40,45,46,50] where patients expressed
concern about the possibility of clinician bias at the time of
consultation, with many of them recalling that either they
were not offered AS as an option or the patient perception of
AS was “doing nothing”. Scherr and colleagues [53]
reviewed patient-physician interactions over the period
that treatment decisions were made and found that
physicians were heavily influenced by age and Gleason
score, but not by the value that patients put on treatment
outcomes, for example, sexual dysfunction.
Parikh and colleagues [36] used the NCDB to review 40
839 men with LRPC in relation to a number of variables.
They found that the barriers to AS included living a longer
distance from the provider facility, and those men were
diagnosed by a physicianworking outside of an academic or
research facility.
3.2.1.5. Healthcare organisation and practice level
3.2.1.5.1. Facilitators and barriers. Many narrative reviews of AS
highlight differences in AS protocols among healthcare
providers and healthcare systems, and also within
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individual countries [11,12,23,26]. For example, the MUSIC
group found that the use of AS varied substantially between
different urology practices in the state of Michigan, ranging
from 27% to 80% of eligible patients [23,26]. This variability
could simply be attributed to the recommendation of the
clinician, but two studies [40,47] focused on access to
clinical expertise and technology, suggesting that patients
felt that they were offered AS only when there was
availability of imaging facilities and expert clinicians to
deliver the AS protocol. A similar diagnostic practice–
related influence was also observed in the Michigan MUSIC
study [23,26].
Type of healthcare system as a barrier to AS was
mentioned in one study [52], which found that the US
system placed limitations on a clinician's ability to
recommend AS (although did not find that this was due
to financial incentives) and carry out the necessary regular
retesting associated with AS. However, Parikh and collea-
gues [36] found that analysis of the NCDB suggested higher
uptake of AS in the uninsured.
3.2.1.6. Health policy level
3.2.1.6.1. Facilitators and barriers. In 2006–2007,Mishra et al [47]
reported that patient and clinician attitudes towards AS
(calculated numerically as a “sentiment index” in the content
in Internet conversations) were at their lowest, with both
judging AS “not safe” and “should only be offered to older
patients”. By 2009,Mishra et al found the Internet sentiment
index was high, meaning that there was a more positive
attitude towards AS. Reasons for this included a 2009 Ameri-
can Urology Association endorsement for AS [57] and a
2010 publication of a large-scale AS cohort [58] reporting a
very low mortality rate over intermediate follow-up. In
Sweden, Loeb and colleagues [11] also found that AS uptake
(2009–2014) significantly increased and hypothesised that
thiswas largelydue tonational guidelines recommendingAS.
3.2.2. Barriers and facilitators to AS adherence
3.2.2.1. Cancer characteristics
3.2.2.1.1. Facilitators. Several population-based studies
reported on cancer characteristics in relation to AS
adherence. The UK-based study, US-based CEASAR study,
and Swedish NPCR [29–31] found that menwith lower PSAs
and tumour staging were more inclined to adhere to AS.
3.2.2.1.2. Barriers. The Swedish NPCR study [29] reported that
the <65-yr age group and those with higher education
levels (<9 yr full-time education) were significantly less
likely to continue AS than the older and less educated
groups. These findings have been replicated in qualitative
studies such as those carried out by Lang et al [31] and
O’Callaghan et al [46], which found that youngermenwith a
higher educational level found the notion of long-term AS,
that is, “doing nothing”, less tolerable than the associated
morbidity of radical treatment. The Swedish NPCR study
[29] also reported that out of those men who discontinued
AS, 52% did so because of PSA progression and 24% due to
biopsy progression.
3.2.2.2. Patient level
3.2.2.2.1. Facilitators. Patient-perceived experience of AS fea-
tured in three studies. Goh et al [50] analysed the
experience of AS in 34 men, and found that those who
viewed their experience with cancer as having a positive
impact on their lives were better able to manage the
uncertainty of AS and felt more in control of their decision
making and during AS. Oliffe et al [59] found that men
reporting a higher level of positivity in the face of their
cancer diagnosis (attributed to consistency in information
and support) were less likely to exhibit decision-making
conflict related to the perceived effectiveness of their
treatment plan and may therefore be more inclined to
remain on AS. These studies suggest that careful patient
selection is important for both treatment choice and
adherence [50,59]. Volk et al [40] found that men described
the process of AS as an organised, supportive process of
regular monitoring.
Four of the seven HRQoL studies had no control group
[60–63]. Wilcox et al [62] and Jeldres et al [64] found no
change in HRQoL before or after entry into an AS
programme. Parker et al [63] found that as age and body
mass index increased, HRQoL decreased over time. Both
Parker et al [63] and Bellardita et al [60] found that HRQoL
improved >5 mo after diagnosis and commencement
of AS.
Bellardita et al [60] also noted that men with a partner
and menwho had >18 biopsy cores taken at diagnosis were
more likely to have good HRQoL on AS. Hegarty et al [61]
compared HRQoL between men on AS in Ireland and the
USA: general HRQoL and vitality were lower in the US
group—which they reported was likely due to differences in
healthcare expectations.
The six studies that included control individuals of either
men with no cancer [65] or those undergoing radical
treatment [66–69] or both [70] showed no statistical
differences in HRQoL between the control individuals and
men on AS. The Finnish section of the Prostate Cancer
Research International: Active Surveillance (PRIAS) study
[65] found better than average HRQoL (as defined by the
RAND-36 questionnaire) than in the general Finnish male
population, both immediately following entry into AS and
1 yr later. Both Vanagas et al [66] and Venderbos et al [67]
reported better HRQoL in men on AS than in men who had
undergone radical treatment with respect to physical,
emotional, and social scales. Donovan and colleagues [68]
reviewed patient-reported outcomes comparing monitor-
ing with surgery and radiotherapy as part of the ProtecT
trial. The monitoring cohort consistently did better with
respect to three of the four domains: erectile, urinary, and
bowel function; however, there was no significant differ-
ence in HRQoL among the three treatment groups. Smith
et al [70] found similar HRQoL scores across AS and
treatment groups. Chen and colleagues [69] reported
similar results recently from the North Carolina Prostate
Cancer Comparative Effectiveness and Survivorship Study
where contemporary PC treatments were compared with
AS in respect of HRQoL. However, after 24mo it was notable
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that QoL scores were not clinically meaningfully different
between the treatment and AS groups.
When measuring the anxiety associated with long-term
surveillance adherence, the majority of studies included in
this review suggested that anxiety reduced [65,66] or
remained the same over time [14,60,62,71–74], with no
observed impact on long-term adherence.
In the recently published ProtecT study, depression was
reported in only 6% of the 545 men allocated to active
monitoring over a period of 10 yr, suggesting that
depression and anxiety do not increase significantly while
on AS [30,75].
A number of studies have shown that emotional
distress is relatively high in men at the time of their PC
diagnosis [33,76]. However, anxiety in men on long-term
AS has generally been reported as favourably low. A
2015 systematic review [77] reported no overall differ-
ence between levels of anxiety following diagnosis of
LRPC and during AS, which was reported as between 4%
and 15%. In fact, more studies have suggested that anxiety
in men on AS reduces [65,66,71] or remains the same over
time [14,60,62,71–74].
3.2.2.2.2. Barriers. The Swedish NPCR study [29] reported that
out of those men who discontinued AS, 20% stopped due to
patient preference alone. The US-based CEASAR study [31],
which included men from five SEER catchment areas, and
the CaPSURE database [31] found that 8–23% of men
converted to curative treatment for reasons of personal
preference rather than disease progression.
These findings were further explored in two large
qualitative studies exploring men's survival expectations
as a result of selecting treatment for LRPC. Xu et al [78]
reviewedmen's perceptions of the likely benefits and harms
of radical treatment versus no treatment (AS). This was
calculated in the form of patient-perceived life expectancy
(LE). At the time of the survey, two-thirds of the 229 men
had started or completed treatment. Of these, 30% in the AS
group expected to live <5 yr. This was in contrast to that in
the treatment group where >95% of patients estimated
their LE to be >5 yr. Kendel et al [79] also reviewed
perceptions of the risk of death from PC between matched
patients who had undergone AS or RP. Men who had
undergone RP estimated the risk of dying from PC
associated with AS to an average of 51%, at least a 10-fold
overestimation of the true risk. They believed that their 10-
yr risk of dying from PC after RP was only one-third of the
risk of AS (18%— also a substantial overestimation). Both
studies thus suggest that patients’ perception of survival is a
barrier to both AS selection and long-term adherence.
Although some studies suggested that “fear of cancer
progression” may be a limiting factor to choosing AS
[59,80–82], none have convincingly shown that this
contributes to a significant number of men opting out of
AS without documented clinical progression (Venderbos
et al [82] found that this was 5%). Both Davison and
Goldenberg [73] and Parker et al [63] found that the degree
of “fear of progression” did not change significantly over a
period of AS.
3.2.2.3. Family and social support
3.2.2.3.1. Facilitators. Four studies highlighted that successful
reassurance and education of the familywas a key facilitator
to patients both in choosing and adhering to AS
[40,45,46]. Loeb et al's [83] qualitative focus group and
interview study found that social support and interaction
(support groups, online forums, support for spouse, and
family) were of particular importance in AS adherence. An
AS support group for both family and men with PC was a
particularly strong recommendation. Mader et al [42]
interviewed 15 men following their decision for AS, and
found a strong correlation between AS adherence and social
support, including spouse, extended family, and experi-
ences of others. Anandadas and colleagues [[15_TD$DIFF]25] further
demonstrated that men were equally as satisfied with their
decision to undertake AS as those who had undergone
radical treatment 2 yr later.
3.2.2.3.2. Barriers. Pressure from family and friends is
reportedly high at the point of diagnosis, many of whom
urge curative treatment [45,47]. The experiences of friends
and family members with cancer (often not PC) are
consistently reported as a significant pressure in men on
AS [45,47]. Berger et al [85] noted that men reported leaving
AS and pursuing treatment to limit their loved ones’ worry,
or in reaction to the fear of cancer expressed by their family.
Partner anxiety was also documented by Seiler et al [86],
who compared levels of anxiety and depression between
men on AS and their partners. Anxiety scores were much
lower in the men than in their partners. The CaPSURE
database [31] found that 16% of men converted to curative
treatment on the basis of “spousal encouragement”.
3.2.2.4. Healthcare provider
3.2.2.4.1. Facilitators. Seven studies identified facilitators to AS
adherence, including education, self-management techni-
ques, healthcare professional, and peer support in the
furtherance of increasing AS adherence. Loeb et al's [83]
combination of focus groups and semistructured interviews
found six themes relating to the facilitation of AS adherence.
Five of these were consistent with healthcare provider
responsibilities in the form of informational needs: (1)
information on PC (biopsy features and prognosis); (2)
information on AS (testing protocol, and difference between
AS and WW); (3) information on complimentary options
(diet and lifestyle); (4) variety of resources (source and
format); and (5) integrity of information (trusted source,
secure, and multidisciplinary). Oliffe et al [59] found that
self-management strategies helped men cope with some of
the long-term uncertainties of AS, while “the Prostate
Cancer Lifestyle Trial” based on lifestyle modifications,
including exercise and attention to stress management,
demonstrated improved treatment-free survival for men on
AS [87]. Goh et al [50] found that men who perceived that
they were receiving useful consistent information were
more satisfiedwith AS and thereforemore likely to continue
on AS. Kinsella and colleagues [88] found that AS classes
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significantly improved long-term adherence to AS, as did
consistency of personnel to support and inform patients, as
found in the UK-based ProtecT trial [89]. Interventions
relating to peer support have also demonstrated a signifi-
cant improvement in the quality of life of men with any
stage of PC [88,89].
3.2.2.4.2. Barriers. The ability of healthcare providers to
deliver long-term support to patients on ASwas highlighted
in several studies [85,90,91]. Men leaving AS describe a
number of unmet supportive care needs [85]. These include
lack of education and clarity concerning the correct time to
pursue treatment, and triggers for treatment from both
patient and relative perspective.
Two studies [90,91] specifically focused on the influence
of support groups. These noted either no effect or even a
negative effect on long-term AS adherence, possibly due to
the group consisting of amix of survivors, that is, those who
had undergone radical treatment and those on AS
[91]. Chapple et al [90] found that support groups were
of no help tomen on AS, with oneman reporting that he felt
he “had to defend himself” in the support group for
choosing AS.
Mishra et al [47] concluded that there was a lack of
availability of consistent and reliable information to men
during long-term AS.
3.2.2.5. Healthcare organisation and practice level
3.2.2.5.1. Facilitators and barriers. Differences in surveillance
strategies have also demonstrated an association with
adherence in both a positive and a negative respect
(Supplementary material, Overview of large cohort active
surveillance studies). These contemporary cohort studies all
include a strategy of repeat biopsy as part of a robust AS
protocol. Two studies found that prostate biopsy was
associated with significant morbidity, and AS adherence
could therefore be influenced by frequency/requirement to
rebiopsy. The ProBE (The effects of prostate biopsy) study
nested within ProtecT assessed patient response to prostate
biopsy and indicated that 25% of men who had undergone
prostate biopsy were disinclined to undergo subsequent
biopsies [48], while a study by Bokhorst et al [92] as part of
the PRIAS study suggested that complications following
prostate biopsy were not uncommon (20% of men), and
after complications men were less likely to accept repeat
biopsy.
However, in two interview-based studies that took place
in the USA [40,46], men gave a consistent description of AS,
viewing it as a reassuring, organised, and supportive
process despite invasive testing.
3.2.2.6. Health policy level
3.2.2.6.1. Facilitators and barriers. AS protocols with respect to
patient selection, safe monitoring, and triggers for inter-
vention vary between study cohorts, healthcare systems,
and countries, which makes it difficult to produce a
coherent, consistent clinical guidance document. In
Sweden, Loeb and colleagues [11] found that AS uptake
and adherence (2009–2014) significantly increased and
hypothesised that this was largely due to clear national
guidelines recommending AS. Likewise, the PRIAS study
[93] suggested improved compliance and adherence as part
of an official AS programme.
3.2.3. Result synthesis
The barriers and facilitators to AS choice and adherence
were categorised into six levels as part of this review: cancer
characteristics, patient, family and social support, provider,
healthcare organisation and practice, and health policy;
these are summarised in Table 4. These barriers and
facilitators varied in both strength of association and level
of evidence, and are described in Figure 3. The barriers and
facilitators identified as most influential over the six levels
are symbolised as circles, with larger circles representing a
greater degree of evidence as supported by this review.
3.3. Discussion
A demonstrable rise in the use of AS has been noted over a
short time frame; however, there are significant differences
between individual healthcare providers as seen in the US
CaPSURE database [5] and Swedish PCBaSe [11]. Local
guidelines, national policy, patient education, supportive
care, and medicolegal factors may be important factors
driving this variation [10,12], and therefore, these issues
require greater consideration and management if we are to
better facilitate AS.
Studies focusing onmen's perception of risk as a barrier to
choosing AS show thatmen continue to grossly overestimate
the risk of dying from LRPCwhile on AS [25,32,45,47]. More-
over, understanding the implications of HRQoL and psycho-
logical factors on the decision to both choose and adhere to
AS requires further multidimensional assessment and
interpretation. Clinicians and patient groups actively en-
courage the increasing responsibility that PC patients are
taking for self-directed management and informed decision
making [87,94]. Such patient empowerment has positive
psychological effects on cancer patients in general and
should be explored in the specific context of AS [87,94].
These elements have been explored in the context of the
chronic disease setting, which one could argue relates well
to a diagnosis of LRPC that may never require curative
treatment. A systematic review of general health screening
and treatment decisionmaking in the chronic disease setting
[95] found that clinicians employing a process of “motiva-
tional interviewing” consistently improved patients’ knowl-
edge, perception of risk, and increased confidence in
decision making. Motivational interviewing is specifically
designed to help patients identify and resolve ambivalence
about changing their behaviour by exploring personal
perspectives and perceived barriers [96]. It employs a
four-step guiding style (engaging, focusing, evoking, and
planning) to foster a constructive clinician-patient relation-
ship. Joosten et al [97] found that motivational interviewing
improved the patients’ ability to self-manage and increased
adherence to chronic disease management plans.
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Table 4 – Summary table of determinants of choice and adherence to active surveillance among men with low-risk prostate cancer found in
the systematic review
Level Factor Potentially targetable interventions for future research




Cancer risk, stage, grade, PSA, tumour volume Harmonising national/local guidelines; developing
consensus-based appropriateness criteria
[11,22–31]
2. Patient Shared or collaborative role in decision
making; preferences; seeking information;
feeling informed; knowledge
Shared decision making; appropriate, reliable, and
unbiased information; personal information; not
contradictory and not stressful; increased availability of
educational resources from trusted medical organisations
for patients and families
[27,32,41,46,50]
Patient characteristics (age, comorbidities,
race, family history of prostate cancer,
education, employment, insurance,
socioeconomic status)
Physician judgement and recommendation in shared
decision making with patient preference
[11,12,22–29,31–37,
40,46,68]
Impact of active treatment on side effects
(urinary function, sexual function);
preservation of HRQoL; time to accept
diagnosis and to decide; “buying time”
Patient education and information. Proactive self-




Self-management support; preference style for
diet, exercise and complimentary therapies;
increased awareness and control of health;
hope for prolonged and improved health;
symptom monitoring; lifestyle
Patient education and information; self-management
through diet and exercise, stress management, digital
technology
[25,32,40,46,50,83]
Preference for immediate cure; “cut it out”;
desiring treatment efﬁcacy/cure; avoid future
regret
Patient education and information; supportive counselling [27,31,40,43,45,80]
Perceived cancer risk; cancer worry; fear of
disease progression; illness uncertainty;
anxiety and distress
Patient education and information; support; coping;
manage anxiety; cognitive reframing; mindfulness;
meditation; empowering; support groups; peer
community; socialisation; connect to others; shared
activities; sense of belonging; providing patients with a
sense of meaning and control, robust monitoring





Monitoring stressors; coping with anxiety,
frequent PSA testing, and repeat biopsies
Patient education and information; support; coping;
development of noninvasive monitoring
[25,27,32,40,
46–48,60,92,93]
Awareness and acceptance of AS; survival
expectation on AS
Availability of AS “success stories” [47,50,59,73,78]




friends; marital status; family member with PC
Supportive counselling and information; patient not
having to justify decision to others; support; education;
reassurance
[32,40–42,45,46,62,85]
Awareness and acceptance of AS Public role models managed with AS and patient advocates [40,42,45–47,85,86]
Fear of progression; disagreement about
safety; preference to “eradicate the cancer”
Counselling and information; enhanced recognition with
information sources, treatment support, medical
consultations
[45–47,50]
4. Provider Physician's recommendation; consistency in
medical/nursing personnel
Training specialists to use a systematic approach to
counselling patients about treatment options;
communicating clearly and with conﬁdence; using
nudging narratives and framing techniques from
behavioural science theory; maintaining a positive and
hopeful attitude; providing support and reassurance;
public reporting of physicians’ cancer management proﬁles
[26,30,32–34,40–42,
44–47,50,52,53,89]
Speciality of physician giving treatment
information
Multidisciplinary team of specialists [22,26,32,56]
Provision of information and support Providing and directing patients to accurate and unbiased
information rather than describing AS as “doing nothing”
or “no treatment” or scaring patients to active treatment,
access to AS support groups. Establishing consistency of
support through nurse specialist roles. Promotion of social
support networks. Access to decisional aids
[26,28,32,40,43,46,
47,50,55,56,59,83,88,89]
Physician attitudes; reluctance; concern about
disease progression; perceived lack of data
Raise awareness, ongoing discussions at national meetings,
quality improvement initiatives; having clear plans and
stopping rules; systematic counselling on AS
[40,44–47,51,52]
Lack of availability of physicians
recommending AS
Advocacy; subspecialty within urology [40,47]
Conﬁdence and trust in health professionals;
closeness with physician; share control over
treatment decision making
Improved community and medical education about
treatment options, prognosis, side effects; raise awareness
of AS; consistent, unbiased treatment information;
decisional support information; building trust in
physician; patient trusting the physician's monitoring;
patient feeling AS is an organised, supportive process
[40,46,51,52,89]
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Although there is currently no published experience of
motivational interviewing in AS, a recent systematic review
in other cancer patients [98] found that it was useful for
eliciting lifestyle behavioural changes, decreasing cancer-
related anxiety, and encouraging supported self-manage-
ment. This also supports that argument that men on AS
experience a similar physical and psychological burden to
people living with other chronic conditions [99], such as
asthma and diabetes [100–104], for whom quality of life
relies on adherence to a treatment plan with the aim to
optimise disease control, maintain quality of life, and
prevent unnecessary escalation of treatment.
Table 4 (Continued )
Level Factor Potentially targetable interventions for future research





Urology practice site; hospital referral region;
geographic region
Quality improvement initiatives to harmonise practice
sites within networks
[26,35–37,46,47]
Degree to which physician shared control over
treatment decision making
System-level determinants of trust, closeness, and shared
decision making; organisational changes (eg, longer
consultation times)
[40,51,52]
Consultation at a multidisciplinary clinic;
university hospital setting; academic hospital
or high volume of PC patients
Multidisciplinary clinic may reduce the bias that specialists
prefer the modality of treatment they themselves deliver
and patients receive a balance perspective of risks and
beneﬁts of options
[11,22,24,35–37]
Differences in surveillance strategies National/international consensus of safe AS. Selection,





Guideline recommendations Harmonising national/local guidelines; developing
appropriateness criteria; national guideline
recommending AS; real-time feedback to units on
adherence to national guideline in terms of annual report
publicly available online
[11,47,52,53]
Trial/cohort data; year of diagnosis Monitoring and future publications from ongoing
prospective protocol-based AS cohorts and registries
[11,35,47,52]
Awareness and acceptance Guidelines; consensus; discussions at meetings; AS-
speciﬁc billing code
[47,52]
AS = active surveillance; HRQoL = health-related quality of life; PC = prostate cancer; PSA = prostate-speciﬁc antigen.
Fig. 3 – Barriers and facilitators to AS choice and adherence; size of circle signifies the strength of evidence for each influencing factor. Yellow circles
indicate that the evidence is strongest for AS choice, green circles indicate that the evidence is strongest for AS adherence, and brown circles indicate that
the evidence is relevant to both AS choice and AS adherence. AS = active surveillance; HRQoL = health-related quality of life; PSA = prostate-specific antigen.
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Another systematic review [100] outlining the merits of
supportive self-management in chronic disease adherence
suggested that there are core components of support and
that their implementation requires a holistic approach,
which intervenes at the level of the patient, the healthcare
professional, and the organisation, much in the sameway as
identified in this review of AS:
1. Provision of education about the long-term condition
(LTC)
2. Psychological strategies to support adjustment to the LTC
3. Practical support tailored to the LTC (eg, support around
activities of daily living for disabling conditions and
action plans in conditions subject to marked exacerba-
tions)
4. Social support
5. Lifestyle modifications (eg, diet and exercise)
Our current systematic review highlights the need for
improved validated methods for patient and physician
education to facilitate the uptake of AS among men with
LRPC. Moreover, studies suggesting that clinician's bias may
influence the treatment decision-making process
[26,32,33,41,46,47,50,51] suggest that educational efforts
aimed at clinicians and frameworks for how they deliver the
information on treatment options [44] are important for
increasing the acceptance of AS. Education, appropriate
information, and support aimed at both patients and their
families have long been recognised as important in the
management of chronic conditions [77,78], with studies
demonstrating an increase in adherence to treatment plans
where these have been established.
In addition, many chronic disease studies have success-
fully explored strategies to reduce healthcare inequalities in
chronic health conditions [103,105,106]. This has been
achieved through the standardisation of education and
training to both clinicians and patients, development of
educational materials and decision aids, as well as creation
of specialist centres for chronic conditions. To date, one
study has replicated this in the context of AS. Formica and
colleagues [107] reported that decision aids in combination
with standardised patient education packages achieved a
three-fold increase in AS acceptance.
Several AS papers suggested that national guidelines
could have a significant impact on selection and adherence
to AS [11,47,93]. This has been replicated in the chronic
disease setting [104,108]. In diabetes management, intro-
duction of the Dutch guidelines increased clinician adher-
ence by 60%, suggesting that guidelines are reassuring for
both patients and clinicians [108]. The current discordance
in ASmanagementmakes internationally ratified guidelines
a priority, and efforts such as those employed by the GAP3
consortium (Movember) [109], which has established active
communication and collaboration among research groups
worldwide, are likely to change this. GAP3 aims to reach
international consensus on the definitions and terms used
in AS through analysis of a global database including >14
000 patients [109].
The requirement for continuous monitoring in AS has
been described as both a barrier and a facilitator. In chronic
disease management, it gave rise to early developments in
telehealth with some studies suggesting that easy-to-learn
applications can improve adherence, lessen disease impact,
accelerate behaviour change to improve outcomes, and
increase patient and partner confidence during remote
monitoring [110,111]. AS monitoring protocols are currently
undergoing rationalisation, withmore frequent imaging and
fewer biopsies. Although we found no reports of the use of
mobile health applications in the AS setting and only one
small pilot of an Internet-based application specifically
aimed atmanaging uncertainty in AS [112], the change in the
way we survey patients could lend itself to the introduction
of robust remote monitoring using this technology.
The role of social media in choice and adherence to AS
has not yet been explored; however, online social networks
have changed the way we communicate and provide new
ways to engage patients. Twitter and Facebook groups
established to engage cancer patients offer easy access to
peer support and have been associated with less stress,
anxiety, and depression [86,87]; in the chronic disease
setting, Kirwan et al [113] found that combining [114]
online applications and social networking significantly
increased diabetic glycaemic control in comparison with
the control group.
A combination of these core elements is critical to
ensuring positive experience and benefit of livingwith LRPC
on AS.
Advances in PC management including the use of
multiparametric MRI, and more sophisticated prostate
biopsy strategies in both diagnostics and surveillance
programmes could also change the level of reassurance in
AS. Alongside this, a recent systematic review focused on the
development of genomic profiling suggests that combining
data of genome-wide association studies with gene expres-
sion and structural rearrangements and risk alleles could
provide a new basis for developing a prognostication tool to
guide therapy for men with LRPC [114].
3.4. Limitations
This review is limited as a mixed-methodology paper. The
included studies were heterogeneous and therefore a meta-
analysis was not possible. This type of systematic review
relies on a reasonable number of included studies for
strength; however, the weighting of individual studies
needs to be adjusted based on the varying levels of evidence
and methodological quality of the included studies.
However, this has been represented using the PREFS quality
checklist and a modified STROBE checklist, which was
reviewed by the three reviewers independently.
Of the papers reviewed, some did not distinguish
entirely between AS and WW, and therefore older age
and comorbidity as facilitators to AS may be inaccurate in
2018. Another limitation concerns the generalisability.
More than 50% of studies were North American, and this
healthcare system may not be generalisable to other
countries.
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4. Conclusions
Many factors influence men's choice and adherence to AS,
such as the clinician's attitudes, family and social support,
and patient education. The clear recommendations of this
review include agreed international guidelines onAS and the
introduction of a multidisciplinary management strategy
with psychological support to facilitate the AS. Current
clinical practice at centres with high AS uptake may provide
insight into the changes required to ultimately decrease the
overtreatment of PC worldwide, while experience gathered
in the chronic disease setting, such as the introduction of
supportive self-management, social media interventions,
and motivational interviewing, could form the blueprint for
future AS programmes to increase both choice of and
adherence to AS in LRPC.
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10.9. Appendix 9 Validated Tools included in systematic review 
Panel 1: 
Overview of Health‐Related Quality of Life (HRQoL) outcomes and their related assessment 
tools. 
HRQoL 
(i) Control Preferences Scale (306) based on five statements to identify the role 
patients had in making the decision to go on AS:  
a. active role with the urologist 
b. a shared or collaborative role with the urologist 
c. a passive role where the urologist made the decision. 
(ii) RAND 36‐Item Short‐Form Health survey version 2 (SF36v2) (307) 
(iii) University of California, Los Angeles Prostate Cancer Index (UCLA‐PCI) (308) 
 
Validated Tool  Purpose  
Control Preferences Scale 
(306) 
To identify the role patients had in making the 
decision to go on AS:  
a. active role with the urologist 
b. a shared or collaborative role with 
the urologist 
c. a passive role where the urologist 
made the decision. 
RAND 36‐Item Short‐Form 
Health survey version 2 
A 36‐Item index, to determine perceived health‐
related quality of life 
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(SF36v2) (307) 
University of California, Los 
Angeles PC Index (UCLA‐PCI) 
(308) 
A 20‐item index to assess prostate treatment 
quality of life 
Panel 2: Validated Tools included in systematic review 
Overview of anxiety outcomes and their related assessment tools. 
Anxiety and decision making 
(i) A measure of the ability to handle symptoms using the self‐efficacy of PC 
symptom management Symptom management (SE) scale (309)  
(ii) An evaluation of depression and contentment with the Mental Health Index – 5 
(MHI‐5) (310) 
(iii) An evaluation of the positive meaning ascribed to cancer with the Fife 
Constructed Meaning Scale (CMS)(311) 
(iv) A measure of illness uncertainty using the Mishel Uncertainty in Illness scale 
(MUIS)(312) 
(v) An evaluation of anxiety using the Memorial Anxiety PC (MAX‐PC)(313).  
(vi) Five decision‐ making scales: decisional regret, decision satisfaction, and three 
aspects of decisional conflict (314‐316). 
(vii) 11 point, analogue distress thermometer (317) which specifically measures 
psychological burden in oncology patients. 
(viii) Sentiment index (317) to evaluate written text, assigning a numerical value 
based upon an assessment of positive, negative, or neutral influences 
Patient trust in physician scale (318) to rate how much they trusted the physician 
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Validated Tool  Purpose 
Symptom 
management (SE) 
scale (309) 
A measure of the ability to handle symptoms using the self‐
efficacy of PC symptom management 
Mental Health Index 
– 5 (MHI‐5) (310) 
An evaluation of depression and contentment 
Fife Constructed 
Meaning Scale 
(CMS) (311) 
An evaluation of the positive meaning ascribed to cancer 
Mishel Uncertainty 
in Illness scale 
(MUIS) (312) 
A measure of illness uncertainty 
Memorial Anxiety PC 
(MAX‐PC) (313) 
An evaluation of anxiety 
Analogue distress 
thermometer (317) 
11 point, which specifically measures psychological burden in 
oncology patients. 
Sentiment index 
(317) 
To evaluate written text, assigning a numerical value based 
upon an assessment of positive, negative, or neutral 
influences 
Patient trust in 
physician scale (318) 
To rate how much they trusted the physician 
Other in self scale 
(IOS) (319) 
A single‐item, pictorial measure of closeness, demonstrated 
alternate‐form and test–retest reliability; convergent validity 
with the Relationship Closeness Inventory  
Five decision‐ 
making scales: (314‐
316). 
Decisional regret, decision satisfaction, and three aspects of 
decisional conflict  
Participatory 
Decision Making 
(PDM) Scale (320) 
3‐ items, asking patients to rate the physicians' propensity to: 
1) involve them in treatment decisions; 2) give them a sense of 
control over medical care; and 3) ask them to take some 
responsibility  
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10.11. Appendix 11 Patient information Sheet and Letter 
 
Study title: Identifying the barriers and facilitators to long‐term active surveillance  
 
You are invited to take part in a service improvement project. Before you decide, it is 
important for you to understand why the research is being carried out and what we will ask 
of you. Please read the following information carefully and discuss it with friends or relatives 
if you wish. 
There are two parts to this information sheet: 
Part 1 
Explains the purpose of this and what your participation in this study will involve. 
Part 2 
Gives you information about how this study will be conducted. 
 
Please ask if there is anything that is not clear or if you would like more information. We 
would advise that you take your time to decide if you would like to participate in this study.  
Thank you for reading this.   
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PART 1 
What is the purpose of the study? 
The purpose of the study is to understand the individual experiences of men on active 
surveillance for prostate cancer and the barriers and facilitators to long‐term adherence to 
active surveillance. 
 
Why have I been invited to participate? 
You have been approached because you dropped out of active surveillance   without 
evidence of your cancer progressing. Your experience would contribute to our understanding 
of why men drop out of surveillance and opt to undergo treatment. The project is designed 
to provide a balanced range of views about this.  
 
Do I have to participate in this project? 
You can choose to participate in this study.  If you do, you have the choice to withdraw from 
it at any time. Your choice will not affect your treatment in any way.  
 
What will happen if I agree to participate in this study? 
If you do agree to participate in this project, Netty Kinsella (Nurse Consultant) will contact 
you by telephone to confirm that you have not changed your decision. You will be invited for 
an interview at the hospital which will be arranged on the same day as your clinic 
appointment where possible. Please let us know if you prefer to have this interview on a 
different day. The interview should take approximately 30 minutes‐1 hour. 
 
During the interview you will be asked to talk about your experience of active surveillance. 
This interview will be audio‐taped. You can say as much or as little as you wish.  
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Refreshments will be provided during the interview.  If you have made a separate journey to 
attend this interview, your travel expenses on public transport will be reimbursed. You will 
need to keep your receipts. 
 
If you agree to participate, Netty Kinsella will look at your medical notes for information 
about your cancer and your treatment. This will help with our interpretation of the 
information you give us.  
 
What will happen to the audio‐tape recordings?  
The audio‐tape recordings will be written in text and an analysis of the findings will be carried 
out. The audio‐tape recordings will not be used for any other purpose. They will be kept 
downloaded on the hospitals secure server and only Netty Kinsella will have access to them. 
We may use anonymous quotes from the interview in the report or future publications.  
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What are the possible benefits of taking part and how will information be used? 
There are no direct personal benefits to the people taking part in this study. However, the 
findings in this project will help to identify areas that need improvement for future patients 
in similar situations.  
If, after discussing your thoughts during the interview, you feel that there are further issues 
you would like to be addressed by your hospital team you can contact Netty to discuss and 
organise this. 
 
What are the possible disadvantages and risks of taking part in the study? 
A possible disadvantage of taking part in the study will be the time commitment for the 
interview.  
Some men may find it difficult discussing issues that may arise, for example anxiety, support, 
family. 
If you feel that you would benefit from additional support following the interview, please 
contact Netty. If appropriate, a referral can be made to your GP or to the psychological 
support service in the hospital.   
 
Is my participation in this study kept confidential? 
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Yes. All information which is collected during the course of the project will be kept strictly 
confidential. Any information arising from the interview will be anonymised. The information 
will be stored on a secure server (in computer files) which can only be accessed by Netty 
Kinsella and the research supervisor, Dr Mieke Van Hemelrijck. This complies with the Data 
Protection Act.  Data will be destroyed fifteen years from the end of the study. 
On rare occasions, something might be revealed during an interview which must be followed 
up. If this should happen, Netty will discuss with you what needs to be done.  
 
What will happen to the results of the research study? 
The results of this quality improvement project will also be part of a thesis written for Netty 
Kinsella’s doctorate at Kings College London, however, your identity will not be revealed. 
Findings will be shared within the Trust and submitted for publication in professional and 
academic journals. Your identity will not be disclosed in any report or publication.   
On completion of the project, feedback will be provided via an information sheet for all 
participants if requested.  
Contact details: 
For general information please contact Netty Kinsella by telephone on xxx xxx extxxxor e‐
mail: netty.kinsella@xxxxxxx.nhs.uk.  
 
This completes part 1 of the information sheet; if the information so far has been of interest 
to you and you are considering participating in it; please continue to read the additional 
information in part two before making any decision.
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PART 2 
What if there is a problem? 
It is unlikely something will go wrong; however any concern, query or complaint about your 
experience while participating in the study will be addressed by Netty Kinsella. Alternatively, 
we can arrange for you to speak to another member of the research team, Dr Mieke 
VanHemelrijck. 
 
Complaints or concerns that have not been answered to your satisfaction can be referred to 
the Complaints Manager, following the complaints procedure for the Royal Marsden 
Hospital. Details of this can be obtained through the Patient Advice & Liaison Service (PALS) 
department on telephone number: xxx xxx. 
 
What will happen if I do not want to continue in the study? 
If at any point you wish to withdraw from the study, you can do so without providing a 
reason. This is not a problem and the researchers will not use any information already 
collected, unless you are happy for them to do so.  You can discuss this with Netty 
Withdrawing from the study will not affect the care you receive in any way.  
 
Who has reviewed the study? 
This study has been reviewed and approved by the Royal Marsden Hospital Quality 
Improvement Project committee. . 
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What should I do now? 
If you are interested in participating in the study or have further questions before making a 
decision, please tell your clinical nurse specialist. Netty is happy to talk to you. 
If you decide to participate in this  project, you will be contacted with a date to meet Netty. 
At this appointment, you will be asked to sign the attached consent form. 
 
Contact Information  
If you would like any further information about this study please contact Netty Kinsella on xxx 
xxxextxxxx or your Clinical Nurse Specialist. 
 
Additionally, the Patient Advice and Liaison Service (PALS) is an independent point of contact 
for all patients who wish to get further advice about the conduct of research studies. The 
PALS centres can be found at xxxxxxxx. They are opened from 9.30am till 4.00pm Monday till 
Friday excluding Bank Holidays. 
 
Thank you for taking the time to read this information sheet. I look forward to hearing from 
you 
 
   
10.12
 
 
Researc
 
Researc
 
Researc
 
Dear……
 
Thank y
will take
particip
any tim
 
Ethical 
intervie
intervie
the pur
Would y
certify t
 
. Append
h project ti
h investiga
h Participa
……….. 
ou for agre
 (up to an 
ation, but y
e.  
procedures
wees explic
w will be us
pose of you
ou therefo
hat you app
ix 12 Pa
tle: Barriers
tor: Netty K
nts name: X
eing to be i
hour). We d
ou have th
 for academ
itly agree t
ed. This co
r involveme
re read the
rove the fo
rticipant
 and facilita
insella 
XXXXXXX 
nterviewed
on’t anticip
e right to st
ic research
o being inte
nsent form
nt and tha
 accompan
llowing: 
 Consen
tors to act
 as part of t
ate that th
op the inte
 undertake
rviewed an
 is necessar
t you agree
ying inform
t Form 
 
ive surveilla
he above r
ere are any
rview or wi
n from UK i
d how the 
y for us to e
 to the con
ation sheet
nce for pro
esearch pro
 risks assoc
thdraw from
nstitutions 
information
nsure that
ditions of yo
 and then s
P
state cance
ject. The in
iated with y
 the resea
require tha
 contained
 you unders
ur particip
ign this for
age 254 
r 
terview 
our 
rch at 
t 
 in their 
tand 
ation. 
m to 
Page 255 
 the interview will be recorded and a transcript will be produced  
 you will be sent the transcript and given the opportunity to correct any factual errors 
 the transcript of the interview will be analysed by (name of the researcher) as 
research investigator 
 access to the interview transcript will be limited to (name of the researcher) and 
academic colleagues and researchers with whom he might collaborate as part of the 
research process 
 any summary interview content, or direct quotations from the interview, that are 
made available through academic publication or other academic outlets will be 
anonymized so that you cannot be identified, and care will be taken to ensure that 
other information in the interview that could identify yourself is not revealed 
 the actual recording will be destroyed  
 
Quotation Agreement: 
I also understand that my words may be quoted directly. With regards to being quoted, 
please initial next to any of the statements that you agree with:  
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 I wish to review the notes, transcripts, or other data collected during the research 
pertaining to my participation.  
 I agree to be quoted directly.  
 I agree to be quoted directly if my name is not published and a made‐up name 
(pseudonym) is used.  
 I agree that the researchers may publish documents that contain quotations by me.  
 All or part of the content of your interview may be used;  
o In academic papers, policy papers or news articles.  
o On our website and in other media that we may produce such as spoken 
presentations.  
o On other feedback events.  
o In an archive of the project as noted above 
 
By signing this form I agree that;  
1. I am voluntarily taking part in this project. I understand that I don’t have to take part, and I 
can stop the interview at any time;  
2. The transcribed interview or extracts from it may be used as described above;  
3. I have read the Information sheet;  
4. I don’t expect to receive any benefit or payment for my participation;  
5. I can request a copy of the transcript of my interview and may make edits I feel necessary 
to ensure the effectiveness of any agreement made about confidentiality;  
6. I have been able to ask any questions I might have, and I understand that I am free to 
contact the researcher with any questions I may have in the future. 
 
Printed Name _____________________________________  
 
Participants Signature_______________________________  
 
Date ____________________________________________   
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Researchers Signature______________________________  
 
Date_____________________________________________  
 
Contact Information: 
This project has been reviewed and approved by the Royal Marsden Quality improvement 
project committee (QIP) 
  
If you have any further questions or concerns about this study, please contact: Netty Kinsella, 
The Royal Marsden Hospital, London, SW3 6JJ Tel: xxxxxxXextXXXXXX  
E‐mail: netty.kinsella@rmh.nhs.uk 
 
You can also contact (Netty Kinsella) supervisor: Mieke.vanhemelrijck@kcl.ac.uk 
 
   
10.13. Appendix 13 Pilot interview coding 
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urveillance ‐ Patient, partner and family survey (No. 2) 
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10.15. Appendix 14 HCP survey 
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